Fcgamma	B-protein
receptor	I-protein
-mediated	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
in	O
monocytes	B-cell_type
is	O
independent	O
of	O
Ras	B-protein
.	O

Receptors	O
for	O
the	O
Fc	B-protein
portion	I-protein
of	O
immunoglobulin	B-protein
molecules	I-protein
(	O
FcR	B-protein
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	B-protein
mediators	I-protein
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O

Cross-linking	O
of	O
FcR	B-protein
with	O
immune	B-protein
complexes	I-protein
leads	O
,	O
first	O
to	O
activation	O
of	O
protein-tyrosine	B-protein
kinases	I-protein
.	O

The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O

We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	B-protein
receptors	I-protein
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	B-protein
in	O
monocytes	B-cell_type
.	O

Cross-linking	O
of	O
FcR	B-protein
,	O
on	O
the	O
THP-1	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
by	O
immune	B-protein
complexes	I-protein
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
and	O
interleukin	B-protein
1	I-protein
production	O
.	O

These	O
responses	O
were	O
completely	O
blocked	O
by	O
tyrosine	B-protein
kinase	I-protein
inhibitors	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
dominant	B-protein
negative	I-protein
mutants	I-protein
of	O
Ras	B-protein
and	O
Raf-1	B-protein
,	O
in	O
these	O
cells	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
FcR	B-protein
-mediated	O
nuclear	B-protein
factor	I-protein
activation	O
,	O
suggesting	O
that	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
signaling	O
pathway	O
was	O
not	O
used	O
by	O
these	O
receptors	O
.	O

However	O
,	O
MAPK	B-protein
activation	O
was	O
easily	O
detected	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
after	O
FcR	B-protein
cross-linking	O
with	O
immune	B-protein
complexes	I-protein
.	O

Using	O
the	O
specific	O
MAPK	B-protein
/extracellular	O
signal-regulated	O
kinase	O
kinase	O
(	O
MAPK	O
kinase	O
)	O
inhibitor	O
PD98059	O
,	O
we	O
found	O
that	O
MAPK	B-protein
activation	O
is	O
necessary	O
for	O
FcR	B-protein
-dependent	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
NF-kappaB	B-protein
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
signaling	O
pathway	O
from	O
Fc	B-protein
receptors	I-protein
leading	O
to	O
expression	O
of	O
different	O
genes	O
important	O
to	O
leukocyte	O
biology	O
,	O
initiates	O
with	O
tyrosine	B-protein
kinases	I-protein
and	O
requires	O
MAPK	B-protein
activation	O
;	O
but	O
in	O
contrast	O
to	O
other	O
tyrosine	B-protein
kinase	I-protein
receptors	I-protein
,	O
FcR	B-protein
-mediated	O
MAPK	B-protein
activation	O
does	O
not	O
involve	O
Ras	B-protein
and	O
Raf	B-protein
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

273	NULL
,	NULL
No	NULL
.	NULL

42	NULL
,	NULL
Issue	NULL
of	NULL
October	NULL
16	NULL
,	NULL
pp	NULL
.	NULL

27610-27619	NULL
,	NULL
1998	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Fcy	NULL
Receptor-mediated	NULL
Mitogen-activated	NULL
Protein	NULL
Kinase	NULL
Activation	NULL
in	NULL
Monocytes	NULL
Is	NULL
Independent	NULL
of	NULL
Ras*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
July	NULL
9	NULL
,	NULL
1998	NULL
)	NULL
Gabriela	NULL
Sanchez-Mejorada	NULL
and	NULL
Carlos	NULL
Rosalest	NULL
From	NULL
the	NULL
Immunology	NULL
Department	NULL
,	NULL
Instituto	NULL
de	NULL
Investigaciones	NULL
Biomédicas	NULL
,	NULL
Universidad	NULL
Nacional	NULL
Auténoma	NULL
de	NULL
México	NULL
,	NULL
Mexico	NULL
City	NULL
04510	NULL
,	NULL
Mexico	NULL
Receptors	NULL
for	NULL
the	NULL
Fc	NULL
portion	NULL
of	NULL
immunoglobulin	NULL
molecules	NULL
(	NULL
FcR	NULL
)	NULL
present	NULL
on	NULL
leukocyte	NULL
cell	NULL
membranes	NULL
mediate	NULL
a	NULL
large	NULL
number	NULL
of	NULL
cellular	NULL
responses	NULL
that	NULL
are	NULL
very	NULL
important	NULL
in	NULL
host	NULL
defense	NULL
,	NULL
including	NULL
phagocytosis	NULL
,	NULL
cell	NULL
cytotoxicity	NULL
,	NULL
production	NULL
and	NULL
secretion	NULL
of	NULL
inflammatory	NULL
mediators	NULL
,	NULL
and	NULL
modulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Cross-linking	NULL
of	NULL
FcR	NULL
with	NULL
immune	NULL
complexes	NULL
leads	NULL
,	NULL
first	NULL
to	NULL
activation	NULL
of	NULL
protein-tyrosine	NULL
kinases	NULL
.	NULL

The	NULL
molecular	NULL
events	NULL
that	NULL
follow	NULL
and	NULL
that	NULL
transduce	NULL
signals	NULL
from	NULL
these	NULL
receptors	NULL
to	NULL
the	NULL
nucleus	NULL
are	NULL
still	NULL
poorly	NULL
defined	NULL
.	NULL

We	NULL
have	NULL
investigated	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
from	NULL
Fc	NULL
receptors	NULL
that	NULL
leads	NULL
to	NULL
gene	NULL
activation	NULL
and	NULL
production	NULL
of	NULL
cytokines	NULL
in	NULL
monocytes	NULL
.	NULL

Cross-linking	NULL
of	NULL
FcR	NULL
,	NULL
on	NULL
the	NULL
THP-1	NULL
monocytic	NULL
cell	NULL
line	NULL
,	NULL
by	NULL
immune	NULL
complexes	NULL
resulted	NULL
in	NULL
both	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
interleukin	NULL
1	NULL
production	NULL
.	NULL

These	NULL
responses	NULL
were	NULL
completely	NULL
blocked	NULL
by	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
expression	NULL
of	NULL
dominant	NULL
negative	NULL
mutants	NULL
of	NULL
Ras	NULL
and	NULL
Raf-1	NULL
,	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
FcR-mediated	NULL
nuclear	NULL
factor	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
signaling	NULL
pathway	NULL
was	NULL
not	NULL
used	NULL
by	NULL
these	NULL
receptors	NULL
.	NULL

However	NULL
,	NULL
MAPK	NULL
activation	NULL
was	NULL
easily	NULL
detected	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
,	NULL
after	NULL
FcR	NULL
cross-linking	NULL
with	NULL
immune	NULL
complexes	NULL
.	NULL

Using	NULL
the	NULL
specific	NULL
MAPK/extracellular	NULL
signal-regulated	NULL
kinase	NULL
kinase	NULL
(	NULL
MAPK	NULL
kinase	NULL
)	NULL
inhibitor	NULL
PD98059	NULL
,	NULL
we	NULL
found	NULL
that	NULL
MAPK	NULL
activation	NULL
is	NULL
necessary	NULL
for	NULL
FcR-dependent	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
suggest	NULL
that	NULL
the	NULL
signaling	NULL
pathway	NULL
from	NULL
Fc	NULL
receptors	NULL
leading	NULL
to	NULL
expression	NULL
of	NULL
different	NULL
genes	NULL
important	NULL
to	NULL
leukocyte	NULL
biology	NULL
,	NULL
initiates	NULL
with	NULL
tyrosine	NULL
kinases	NULL
and	NULL
requires	NULL
MAPK	NULL
activation	NULL
;	NULL
but	NULL
in	NULL
contrast	NULL
to	NULL
other	NULL
tyrosine	NULL
kinase	NULL
receptors	NULL
,	NULL
FcR-mediated	NULL
MAPK	NULL
activation	NULL
does	NULL
not	NULL
involve	NULL
Ras	NULL
and	NULL
Raf	NULL
.	NULL

Antibodies	NULL
(	NULL
immunoglobulins	NULL
)	NULL
present	NULL
two	NULL
main	NULL
functions	NULL
in	NULL
host	NULL
defense	NULL
:	NULL
the	NULL
binding	NULL
to	NULL
antigen	NULL
via	NULL
their	NULL
antigen-combin-ing	NULL
sites	NULL
and	NULL
the	NULL
mobilization	NULL
of	NULL
cellular	NULL
defense	NULL
mechanisms	NULL
via	NULL
their	NULL
carboxyl-terminal	NULL
Fe	NULL
portion	NULL
.	NULL

Cross-linking	NULL
of	NULL
receptors	NULL
for	NULL
the	NULL
Fc	NULL
portion	NULL
of	NULL
immunoglobulin	NULL
G	NULL
molecules	NULL
(	NULL
Fe	NULL
’	NULL
yR	NULL
)	NULL
1	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant	NULL
2356P/N	NULL
from	NULL
Consejo	NULL
Nacional	NULL
de	NULL
Ciencia	NULL
y	NULL
Tecnologia	NULL
and	NULL
Grant	NULL
IN201797	NULL
from	NULL
Direccion	NULL
General	NULL
de	NULL
Asuntos	NULL
del	NULL
Personal	NULL
Académio	NULL
,	NULL
Universidad	NULL
Nacional	NULL
Auténoma	NULL
de	NULL
México	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1784	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dept	NULL
.	NULL

of	NULL
Immunol-ogy	NULL
,	NULL
Instituto	NULL
de	NULL
Investigaciones	NULL
Biomédicas	NULL
,	NULL
Universidad	NULL
Nacional	NULL
Autonoma	NULL
de	NULL
México	NULL
,	NULL
Apto	NULL
.	NULL

Postal	NULL
70228	NULL
,	NULL
Cd	NULL
.	NULL

Universitaria	NULL
,	NULL
México	NULL
D.F	NULL
.	NULL

04510	NULL
,	NULL
Mexico	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
52-5-622-8888	NULL
;	NULL
Fax	NULL
:	NULL
52-5-622-3869	NULL
;	NULL
E-mail	NULL
:	NULL
carosal	NULL
@	NULL
servidor.unam.mx	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
FeyR	NULL
,	NULL
receptor	NULL
(	NULL
s	NULL
)	NULL
for	NULL
the	NULL
Fc	NULL
portion	NULL
of	NULL
immunoglobulin	NULL
G	NULL
molecules	NULL
;	NULL
ERK	NULL
,	NULL
extracellular	NULL
signal-regulated	NULL
ki-	NULL
27610	NULL
on	NULL
many	NULL
cells	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
triggers	NULL
various	NULL
functions	NULL
such	NULL
as	NULL
phagocytosis	NULL
,	NULL
antibody-dependent	NULL
cell-mediated	NULL
cytotoxicity	NULL
,	NULL
generation	NULL
of	NULL
the	NULL
respiratory	NULL
burst	NULL
,	NULL
and	NULL
production	NULL
of	NULL
inflammatory	NULL
mediators	NULL
and	NULL
cytokines	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

Three	NULL
classes	NULL
of	NULL
FceyR	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
FeyRI	NULL
(	NULL
CD64	NULL
)	NULL
,	NULL
FcyRII	NULL
(	NULL
CD32	NULL
)	NULL
,	NULL
and	NULL
FcyRIII	NULL
(	NULL
CD16	NULL
)	NULL
.	NULL

They	NULL
are	NULL
coded	NULL
for	NULL
by	NULL
different	NULL
genes	NULL
and	NULL
differ	NULL
in	NULL
their	NULL
relative	NULL
avidity	NULL
for	NULL
IgG	NULL
,	NULL
molecular	NULL
structure	NULL
,	NULL
and	NULL
cellular	NULL
distribution	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
FcyR	NULL
as	NULL
well	NULL
as	NULL
other	NULL
immunoreceptors	NULL
(	NULL
such	NULL
as	NULL
TCR	NULL
,	NULL
BCR	NULL
,	NULL
and	NULL
FeeRI	NULL
)	NULL
results	NULL
in	NULL
common	NULL
molecular	NULL
events	NULL
involving	NULL
activation	NULL
of	NULL
Src	NULL
family	NULL
kinases	NULL
followed	NULL
by	NULL
activation	NULL
of	NULL
Syk	NULL
family	NULL
kinases	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
particular	NULL
kinases	NULL
involved	NULL
depend	NULL
on	NULL
the	NULL
particular	NULL
immunoreceptor	NULL
tyrosine-based	NULL
activation	NULL
motif	NULL
(	NULL
ITAM	NULL
)	NULL
present	NULL
on	NULL
the	NULL
cytoplasmic	NULL
portion	NULL
of	NULL
each	NULL
receptor	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

After	NULL
FcyR	NULL
aggregation	NULL
and	NULL
activation	NULL
of	NULL
protein-tyrosine	NULL
kinases	NULL
(	NULL
10	NULL
)	NULL
,	NULL
several	NULL
substrates	NULL
are	NULL
phosphorylated	NULL
and	NULL
other	NULL
enzymes	NULL
are	NULL
also	NULL
activated	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
phospholipase	NULL
C	NULL
yl	NULL
and	NULL
y2	NULL
(	NULL
11-14	NULL
)	NULL
,	NULL
phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
,	NULL
and	NULL
paxillin	NULL
(	NULL
17	NULL
)	NULL
,	NULL
a	NULL
cytoskeletal	NULL
protein	NULL
,	NULL
have	NULL
all	NULL
been	NULL
reported	NULL
.	NULL

One	NULL
of	NULL
the	NULL
major	NULL
cellular	NULL
responses	NULL
initiated	NULL
by	NULL
FoyR	NULL
cross-linking	NULL
,	NULL
specially	NULL
in	NULL
myelomonocytic	NULL
and	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
,	NULL
is	NULL
the	NULL
activation	NULL
of	NULL
genes	NULL
encoding	NULL
cytokines	NULL
important	NULL
in	NULL
inflammation	NULL
,	NULL
such	NULL
as	NULL
interleukin	NULL
1	NULL
(	NULL
IL-1	NULL
)	NULL
,	NULL
IL-8	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
(	NULL
2	NULL
,	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

The	NULL
signaling	NULL
pathway	NULL
from	NULL
FcyR	NULL
to	NULL
the	NULL
nucleus	NULL
is	NULL
not	NULL
known	NULL
,	NULL
but	NULL
it	NULL
probably	NULL
shares	NULL
elements	NULL
with	NULL
the	NULL
biochemical	NULL
cascade	NULL
used	NULL
by	NULL
other	NULL
receptors	NULL
known	NULL
to	NULL
activate	NULL
gene	NULL
transcription	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
receptors	NULL
with	NULL
intrinsic	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
transcription	NULL
of	NULL
genes	NULL
via	NULL
activation	NULL
of	NULL
the	NULL
Ras	NULL
signaling	NULL
pathway	NULL
(	NULL
20	NULL
)	NULL
,	NULL
which	NULL
turns	NULL
on	NULL
sequentially	NULL
Ras	NULL
,	NULL
Raf-1	NULL
,	NULL
MEK	NULL
,	NULL
and	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

MAPK	NULL
,	NULL
also	NULL
known	NULL
as	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
(	NULL
23	NULL
)	NULL
phosphorylates	NULL
and	NULL
activates	NULL
several	NULL
transcription	NULL
factors	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
recent	NULL
reports	NULL
indicate	NULL
that	NULL
MAPK	NULL
is	NULL
activated	NULL
after	NULL
FoyR	NULL
cross-linking	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
26-32	NULL
)	NULL
,	NULL
it	NULL
has	NULL
been	NULL
assumed	NULL
that	NULL
the	NULL
classical	NULL
Ras	NULL
pathway	NULL
is	NULL
activated	NULL
upon	NULL
FcR	NULL
signaling	NULL
.	NULL

However	NULL
,	NULL
no	NULL
direct	NULL
proof	NULL
that	NULL
Ras	NULL
is	NULL
used	NULL
in	NULL
FeyR	NULL
signaling	NULL
has	NULL
been	NULL
provided	NULL
,	NULL
except	NULL
for	NULL
a	NULL
single	NULL
report	NULL
on	NULL
NK	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Because	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
IL-1	NULL
gene	NULL
induction	NULL
(	NULL
34-36	NULL
)	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
investigate	NULL
directly	NULL
if	NULL
FeyR	NULL
cross-linking	NULL
on	NULL
monocytic	NULL
cells	NULL
resulted	NULL
in	NULL
activation	NULL
of	NULL
this	NULL
nuclear	NULL
factor	NULL
,	NULL
and	NULL
then	NULL
we	NULL
used	NULL
this	NULL
nase	NULL
;	NULL
HA-MAPK	NULL
,	NULL
MAPK	NULL
containing	NULL
the	NULL
influenza	NULL
hemagglutinin	NULL
epitope	NULL
tag	NULL
;	NULL
IL-1	NULL
,	NULL
interleukin	NULL
1	NULL
;	NULL
IL-8	NULL
,	NULL
interleukin	NULL
8	NULL
;	NULL
MAPK	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
;	NULL
MAP	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
;	NULL
MEK	NULL
,	NULL
MAPK/ERK	NULL
kinase	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
MBP	NULL
,	NULL
myelin	NULL
basic	NULL
protein	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
GFP	NULL
,	NULL
green	NULL
fluorescent	NULL
protein	NULL
;	NULL
HA	NULL
,	NULL
hemagglutinin	NULL
;	NULL
ELISA	NULL
,	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
;	NULL
NK	NULL
,	NULL
natural	NULL
killer	NULL
;	NULL
NF-xB	NULL
,	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
;	NULL
IIC	NULL
,	NULL
insoluble	NULL
immune	NULL
complex	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
response	NULL
as	NULL
a	NULL
final	NULL
read-out	NULL
to	NULL
examine	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
several	NULL
elements	NULL
of	NULL
the	NULL
Ras	NULL
pathway	NULL
in	NULL
FcyR	NULL
signaling	NULL
,	NULL
leading	NULL
to	NULL
gene	NULL
activation	NULL
and	NULL
cytokine	NULL
production	NULL
.	NULL

We	NULL
found	NULL
that	NULL
stimulation	NULL
of	NULL
the	NULL
THP-1	NULL
monocytic	NULL
cell	NULL
line	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
results	NULL
in	NULL
production	NULL
of	NULL
IL-1	NULL
and	NULL
also	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-kB	NULL
.	NULL

Moreover	NULL
,	NULL
activation	NULL
of	NULL
this	NULL
nuclear	NULL
factor	NULL
is	NULL
mediated	NULL
by	NULL
MAPK	NULL
but	NULL
activation	NULL
of	NULL
this	NULL
kinase	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
involve	NULL
the	NULL
classical	NULL
Ras	NULL
pathway	NULL
defined	NULL
for	NULL
other	NULL
receptor	NULL
tyrosine	NULL
kinases	NULL
(	NULL
20	NULL
,	NULL
37	NULL
)	NULL
,	NULL
since	NULL
expression	NULL
of	NULL
dominant	NULL
negative	NULL
mutants	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
either	NULL
MAPK	NULL
activation	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
MAPK	NULL
kinase	NULL
(	NULL
MEK	NULL
)	NULL
specific	NULL
inhibitor	NULL
,	NULL
PD98059	NULL
,	NULL
efficiently	NULL
blocked	NULL
activation	NULL
of	NULL
this	NULL
nuclear	NULL
factor	NULL
to	NULL
basal	NULL
levels	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
MAPK	NULL
is	NULL
an	NULL
important	NULL
element	NULL
in	NULL
FoyR	NULL
-mediated	NULL
induction	NULL
of	NULL
cytokine	NULL
genes	NULL
(	NULL
e.g	NULL
.	NULL

IL-1	NULL
)	NULL
in	NULL
monocytes	NULL
,	NULL
and	NULL
strongly	NULL
suggest	NULL
that	NULL
activation	NULL
of	NULL
MEK	NULL
and	NULL
subsequently	NULL
of	NULL
MAPK	NULL
occurs	NULL
via	NULL
a	NULL
pathway	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Plasmids	NULL
and	NULL
Reagents-The	NULL
following	NULL
antibodies	NULL
were	NULL
used	NULL
:	NULL
Anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
(	NULL
catalog	NULL
no	NULL
.	NULL

E171120	NULL
,	NULL
Transduction	NULL
Lab-oratories	NULL
,	NULL
Lexington	NULL
,	NULL
KY	NULL
)	NULL
,	NULL
horseradish	NULL
peroxidase-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Cappel	NULL
,	NULL
Aurora	NULL
,	NULL
OH	NULL
)	NULL
The	NULL
specific	NULL
MEK	NULL
(	NULL
MAPK	NULL
kinase	NULL
)	NULL
inhibitor	NULL
PD98059	NULL
was	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Inc.	NULL
(	NULL
Bev-erly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
plasmids	NULL
HIV-lue	NULL
and	NULL
El8pal-luec	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
John	NULL
Westwick	NULL
and	NULL
Dr.	NULL
David	NULL
A.	NULL
Brenner	NULL
of	NULL
the	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
NC	NULL
.	NULL

HIV-lue	NULL
contains	NULL
NF-	NULL
«	NULL
B-responsive	NULL
elements	NULL
within	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
promoter	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
(	NULL
luc	NULL
)	NULL
gene	NULL
and	NULL
directs	NULL
the	NULL
expression	NULL
of	NULL
luciferase	NULL
in	NULL
response	NULL
to	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

El8pal-lue	NULL
that	NULL
activates	NULL
luciferase	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
the	NULL
nuclear	NULL
factor	NULL
Ets	NULL
.	NULL

The	NULL
plasmid	NULL
encoding	NULL
HA-MAPK	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Mike	NULL
Weber	NULL
from	NULL
the	NULL
University	NULL
of	NULL
Virginia	NULL
,	NULL
Charlottesville	NULL
,	NULL
VA.	NULL
Plasmids	NULL
that	NULL
direct	NULL
the	NULL
synthesis	NULL
of	NULL
normal	NULL
or	NULL
mutant	NULL
forms	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
Channing	NULL
Der	NULL
from	NULL
the	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
NC	NULL
.	NULL

Ras	NULL
constructs	NULL
were	NULL
all	NULL
cloned	NULL
in	NULL
the	NULL
retro-viral	NULL
vector	NULL
pZIP	NULL
.	NULL

The	NULL
Ras	NULL
N17	NULL
(	NULL
asparagine	NULL
17	NULL
)	NULL
mutant	NULL
is	NULL
a	NULL
dominant	NULL
negative	NULL
form	NULL
of	NULL
this	NULL
gene	NULL
,	NULL
while	NULL
the	NULL
Ras	NULL
L61	NULL
(	NULL
leucine	NULL
61	NULL
)	NULL
mutant	NULL
is	NULL
an	NULL
active	NULL
oncogenic	NULL
form	NULL
(	NULL
88	NULL
)	NULL
.	NULL

The	NULL
Raf	NULL
28-284	NULL
construct	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
amino-terminal	NULL
domain	NULL
of	NULL
Raf-1	NULL
and	NULL
acts	NULL
as	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
(	NULL
39	NULL
)	NULL
,	NULL
was	NULL
cloned	NULL
in	NULL
the	NULL
pCGN	NULL
vector	NULL
.	NULL

To	NULL
test	NULL
the	NULL
dominant	NULL
negative	NULL
mutants	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
Ras	NULL
pathway-respon-sive	NULL
reporter	NULL
system	NULL
GAL-EIk/5XGal-luc	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
pEGFP-N1	NULL
(	NULL
CLONTECH	NULL
)	NULL
containing	NULL
the	NULL
cDNA	NULL
for	NULL
the	NULL
green	NULL
fluorescent	NULL
protein	NULL
(	NULL
GFP	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
David	NULL
Garcia	NULL
Diaz	NULL
from	NULL
the	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Mexico	NULL
,	NULL
Mexico	NULL
City	NULL
.	NULL

All	NULL
other	NULL
chemicals	NULL
were	NULL
from	NULL
Sigma	NULL
.	NULL

Insoluble	NULL
Immune	NULL
Complexes-Insoluble	NULL
immune	NULL
complexes	NULL
(	NULL
IIC	NULL
)	NULL
were	NULL
prepared	NULL
by	NULL
mixing	NULL
300	NULL
pl	NULL
of	NULL
rabbit	NULL
anti-horse	NULL
ferritin	NULL
antibody	NULL
(	NULL
28	NULL
mg/ml	NULL
)	NULL
(	NULL
Miles	NULL
Laboratories	NULL
Ltd.	NULL
,	NULL
Slough	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
and	NULL
30	NULL
ul	NULL
of	NULL
horse	NULL
ferritin	NULL
type	NULL
I	NULL
(	NULL
100	NULL
mg/m	NULL
!	NULL
)	NULL

(	NULL
Sigma	NULL
)	NULL
in	NULL
Eppendorf	NULL
tubes	NULL
and	NULL
incubating	NULL
at	NULL
37°C	NULL
for	NULL
60	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
12	NULL
h	NULL
on	NULL
ice	NULL
.	NULL

Insoluble	NULL
immune	NULL
complexes	NULL
were	NULL
separated	NULL
by	NULL
centrifugation	NULL
at	NULL
20,000	NULL
x	NULL
g	NULL
and	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
sterile	NULL
PBS	NULL
.	NULL

IIC	NULL
were	NULL
resuspended	NULL
in	NULL
750	NULL
ul	NULL
of	NULL
PBS	NULL
and	NULL
kept	NULL
sterile	NULL
at	NULL
4	NULL
°C	NULL
until	NULL
use	NULL
.	NULL

Preparation	NULL
of	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
Fragments-Anti-ferritin	NULL
antibodies	NULL
were	NULL
subjected	NULL
to	NULL
pepsin	NULL
digestion	NULL
to	NULL
prepare	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragments	NULL
.	NULL

Briefly	NULL
,	NULL
2.8	NULL
mg	NULL
were	NULL
dissolved	NULL
in	NULL
0.1	NULL
M	NULL
citrate	NULL
buffer	NULL
,	NULL
pH	NULL
3.5	NULL
,	NULL
and	NULL
pepsin	NULL
(	NULL
EC	NULL
3.4.23.1	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
at	NULL
25	NULL
ug/ml	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
37	NULL
°C	NULL
for	NULL
4	NULL
h	NULL
and	NULL
then	NULL
neutralized	NULL
with	NULL
3	NULL
M	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
=	NULL
8.6	NULL
.	NULL

Undigested	NULL
antibody	NULL
was	NULL
separated	NULL
in	NULL
a	NULL
protein	NULL
A-Sepharose	NULL
column	NULL
.	NULL

Purity	NULL
of	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragments	NULL
was	NULL
confirmed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Cell	NULL
Culture-The	NULL
human	NULL
monocytic	NULL
THP-1	NULL
cell	NULL
line	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat	NULL
inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
20	NULL
pM	NULL
glutamine	NULL
,	NULL
50	NULL
units/ml	NULL
penicillin	NULL
,	NULL
and	NULL
50	NULL
ug/ml	NULL
streptomycin	NULL
.	NULL

IL-1	NULL
Measurement-THP-1	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
40	NULL
ul	NULL
insoluble	NULL
immune	NULL
complexes	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
complete	NULL
medium	NULL
for	NULL
various	NULL
times	NULL
(	NULL
0-48	NULL
h	NULL
)	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
time	NULL
,	NULL
cells	NULL
were	NULL
centrifuged	NULL
at	NULL
20,000	NULL
x	NULL
g	NULL
and	NULL
the	NULL
supernatant	NULL
collected	NULL
and	NULL
immediately	NULL
frozen	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

Interleukin	NULL
1	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
supernatants	NULL
with	NULL
an	NULL
ELISA	NULL
kit	NULL
(	NULL
Amersham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

In	NULL
some	NULL
exper-	NULL
27611	NULL
iments	NULL
,	NULL
30	NULL
um	NULL
PD98059	NULL
or	NULL
10	NULL
uM	NULL
herbimycin	NULL
A	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
was	NULL
added	NULL
1	NULL
h	NULL
before	NULL
stimulation	NULL
.	NULL

Transfections-THP-1	NULL
monocytic	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
DEAE-dextran	NULL
method	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
1	NULL
X	NULL
10°	NULL
cells	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
by	NULL
incubating	NULL
cells	NULL
with	NULL
200	NULL
ug/ml	NULL
DEAE-dextran	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Uppsala	NULL
Sweden	NULL
)	NULL
for	NULL
60	NULL
min	NULL
and	NULL
after	NULL
one	NULL
wash	NULL
,	NULL
with	NULL
0.1	NULL
mM	NULL
chloroquine	NULL
for	NULL
another	NULL
hour	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Twenty-four	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
and	NULL
stimulated	NULL
with	NULL
40	NULL
ul	NULL
of	NULL
insoluble	NULL
immune	NULL
complexes	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
after	NULL
a	NULL
5-h	NULL
incubation	NULL
at	NULL
37	NULL
°C	NULL
and	NULL
lysed	NULL
with	NULL
65	NULL
ul	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
0.1	NULL
M	NULL
Tris-HCl	NULL
pH	NULL
7.8	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
transfection	NULL
efficiencies	NULL
in	NULL
selected	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
plasmid	NULL
pGL3	NULL
control	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
,	NULL
which	NULL
constitutively	NULL
expresses	NULL
luciferase	NULL
from	NULL
the	NULL
SV40	NULL
promoter	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
transfected	NULL
with	NULL
the	NULL
plasmid	NULL
pEGFP-N1	NULL
(	NULL
CLONTECH	NULL
)	NULL
containing	NULL
the	NULL
cDNA	NULL
for	NULL
the	NULL
green	NULL
fluorescent	NULL
protein	NULL
(	NULL
GFP	NULL
)	NULL
under	NULL
control	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
.	NULL

Efficiency	NULL
was	NULL
estimated	NULL
from	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
presenting	NULL
green	NULL
fluorescence	NULL
at	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Luciferase	NULL
Activity-Luciferase	NULL
enzymatic	NULL
activity	NULL
was	NULL
determined	NULL
in	NULL
cell	NULL
lysates	NULL
using	NULL
a	NULL
luminometer	NULL
(	NULL
Monolight	NULL
2010	NULL
Luminometer	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
50	NULL
ul	NULL
of	NULL
cell	NULL
lysate	NULL
were	NULL
mixed	NULL
with	NULL
100	NULL
ul	NULL
of	NULL
buffer	NULL
(	NULL
30	NULL
mM	NULL
triglycine	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
3	NULL
mM	NULL
ATP	NULL
,	NULL
15	NULL
mm	NULL
MgSO	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
dithiothre-itol	NULL
)	NULL
,	NULL
and	NULL
100	NULL
ul	NULL
of	NULL
substrate	NULL
(	NULL
250	NULL
uM	NULL
D-luciferin	NULL
,	NULL
pH	NULL
6.5	NULL
)	NULL
.	NULL

Light	NULL
produced	NULL
was	NULL
measured	NULL
during	NULL
20	NULL
s.	NULL
Cell	NULL
Lysates-Cells	NULL
were	NULL
lysed	NULL
in	NULL
RIPA	NULL
buffer	NULL
(	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
50	NULL
mm	NULL
HEPES	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
deoxycholate	NULL
,	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
10	NULL
mM	NULL
2-mercaptoethanol	NULL
,	NULL
pH	NULL
=	NULL
7.5	NULL
)	NULL
containing	NULL
1	NULL
mM	NULL
sodium	NULL
vanadate	NULL
,	NULL
1	NULL
mM	NULL
p-nitrophenyl	NULL
phosphate	NULL
,	NULL
2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
50	NULL
ug/ml	NULL
aprotinin	NULL
A	NULL
,	NULL
25	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
25	NULL
ug/ml	NULL
pepstatin	NULL
,	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
then	NULL
cleared	NULL
by	NULL
centrifugation	NULL
at	NULL
20,000	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
and	NULL
kept	NULL
cold	NULL
on	NULL
ice	NULL
.	NULL

Western	NULL
Blot-Total	NULL
cell	NULL
lysates	NULL
or	NULL
MAP	NULL
kinase	NULL
immunoprecipitates	NULL
were	NULL
resolved	NULL
on	NULL
12	NULL
%	NULL
SDS-PAGE	NULL
.	NULL

Proteins	NULL
were	NULL
then	NULL
electrotrans-ferred	NULL
onto	NULL
polyvinylidene	NULL
difluoride	NULL
membranes	NULL
(	NULL
Immobilon-P	NULL
;	NULL
Milli-pore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Membranes	NULL
were	NULL
incubated	NULL
in	NULL
blocking	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
5	NULL
%	NULL
nonfat	NULL
dry	NULL
milk	NULL
(	NULL
Carnation	NULL
;	NULL
Nestle	NULL
Food	NULL
Co.	NULL
,	NULL
Glendde	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
in	NULL
PBS	NULL
)	NULL
overnight	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Membranes	NULL
were	NULL
subsequently	NULL
probed	NULL
with	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
at	NULL
0.1	NULL
ug/ml	NULL
in	NULL
blocking	NULL
buffer	NULL
,	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Membranes	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
six	NULL
times	NULL
for	NULL
5	NULL
min	NULL
each	NULL
and	NULL
incubated	NULL
with	NULL
horseradish	NULL
peroxidase-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Cappel	NULL
,	NULL
Aurora	NULL
,	NULL
OH	NULL
)	NULL
,	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

After	NULL
washing	NULL
six	NULL
more	NULL
times	NULL
with	NULL
PBS	NULL
,	NULL
antibody-reactive	NULL
proteins	NULL
were	NULL
detected	NULL
with	NULL
a	NULL
chemiluminescence	NULL
substrate	NULL
(	NULL
Pierce	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Anti-phosphotyrosine	NULL
Monoclonal	NULL
Antibodies-A	NULL
series	NULL
of	NULL
new	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
anti-phosphotyrosine	NULL
were	NULL
obtained	NULL
following	NULL
standard	NULL
techniques	NULL
(	NULL
42	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
BALB/c	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
phosphotyrosine-coupled	NULL
KLH	NULL
in	NULL
Freund	NULL
's	NULL
adjuvant	NULL
.	NULL

Splenocytes	NULL
from	NULL
these	NULL
animals	NULL
were	NULL
fused	NULL
to	NULL
SP2/0	NULL
myeloma	NULL
cells	NULL
and	NULL
hybridomas	NULL
selected	NULL
by	NULL
ELISA	NULL
.	NULL

Positive	NULL
hybridomas	NULL
secreted	NULL
antibodies	NULL
binding	NULL
to	NULL
phosphotyrosine-coupled	NULL
ovalbumin	NULL
,	NULL
but	NULL
not	NULL
to	NULL
tyrosine-coupled	NULL
ovalbumin	NULL
.	NULL

Several	NULL
hybridomas	NULL
were	NULL
cloned	NULL
and	NULL
characterized	NULL
.	NULL

Clone	NULL
AFT8	NULL
,	NULL
an	NULL
IgG1	NULL
producer	NULL
,	NULL
was	NULL
selected	NULL
for	NULL
anti-phosphotyrosine	NULL
Western	NULL
blots	NULL
.	NULL

Monoclonal	NULL
antibody	NULL
AFT8	NULL
was	NULL
purified	NULL
from	NULL
ascitis	NULL
fluid	NULL
by	NULL
affinity	NULL
chromatography	NULL
in	NULL
a	NULL
protein	NULL
A-Sepharose	NULL
column	NULL
.	NULL

Immune	NULL
Complex	NULL
Kinase	NULL
Assay-MAP	NULL
kinase	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
THP-1	NULL
cell	NULL
lysates	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
cell	NULL
equivalent	NULL
)	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
.	NULL

The	NULL
antibody	NULL
was	NULL
first	NULL
incubated	NULL
with	NULL
20	NULL
ul	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
,	NULL
and	NULL
then	NULL
mixed	NULL
with	NULL
the	NULL
cell	NULL
lysate	NULL
for	NULL
another	NULL
2	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Sepharose	NULL
beads	NULL
were	NULL
then	NULL
washed	NULL
once	NULL
with	NULL
cold	NULL
RIPA	NULL
buffer	NULL
and	NULL
four	NULL
more	NULL
times	NULL
with	NULL
cold	NULL
washing	NULL
buffer	NULL
(	NULL
0.25	NULL
M	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
0.1	NULL
M	NULL
NaCl	NULL
)	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
resuspended	NULL
in	NULL
40	NULL
ul	NULL
of	NULL
kinase	NULL
assay	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
10	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
25	NULL
uM	NULL
ATP	NULL
)	NULL
,	NULL
containing	NULL
5	NULL
wCi	NULL
of	NULL
[	NULL
y-°°P	NULL
]	NULL
JATP	NULL
(	NULL
1.11	NULL
TBq/mmol	NULL
;	NULL
2	NULL
mCi/ml	NULL
)	NULL
(	NULL
NEN	NULL
Life	NULL
Science	NULL
Products	NULL
)	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Reaction	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
30	NULL
ul	NULL
of	NULL
3X	NULL
SDS	NULL
sample	NULL
buffer	NULL
and	NULL
boiling	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Samples	NULL
were	NULL
electrophoresed	NULL
on	NULL
12	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
.	NULL

The	NULL
phosphorylated	NULL
substrate	NULL
bands	NULL
were	NULL
analyzed	NULL
by	NULL
autoradiogra-phy	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
amount	NULL
of	NULL
protein	NULL
immunoprecipitated	NULL
,	NULL
an	NULL
aliquot	NULL
of	NULL
the	NULL
sample	NULL
was	NULL
separated	NULL
and	NULL
Western	NULL
blotted	NULL
with	NULL
anti-MAPK	NULL
antibodies	NULL
.	NULL

HA-MAPK	NULL
Immune	NULL
Complex	NULL
Kinase	NULL
Assay-In	NULL
some	NULL
experiments	NULL
,	NULL
HA	NULL
epitope-tagged	NULL
MAP	NULL
kinase	NULL
was	NULL
transfected	NULL
into	NULL
THP-1	NULL
cells	NULL
.	NULL

After	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27612	NULL
--	NULL
-	NULL
_	NULL
1C	NULL
--	NULL
#	NULL
=-	NULL
_	NULL
HC	NULL
+	NULL
Herb	NULL
.	NULL

A	NULL
--	NULL
o-	NULL
+	NULL
490	NULL
Medium	NULL
=	NULL
=	NULL
390	NULL
3	NULL
~	NULL
I	NULL
2	NULL
290	NULL
--	NULL
U	NULL
190	NULL
90	NULL
10	NULL
T	NULL
@	NULL
-	NULL
#	NULL
-	NULL
q	NULL
0	NULL
8	NULL
16	NULL
2	NULL
4	NULL
3	NULL
2	NULL
4	NULL
0	NULL
4	NULL
8	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Fey	NULL
receptor	NULL
stimulation	NULL
induces	NULL
interleukin	NULL
1	NULL
production	NULL
.	NULL

1	NULL
X	NULL
10°	NULL
THP-1	NULL
cells	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
complete	NULL
medium	NULL
were	NULL
incubated	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
medium	NULL
)	NULL
(	NULL
0	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
40	NULL
ul	NULL
of	NULL
IIC	NULL
(	NULL
@	NULL
)	NULL
.	NULL

IL-1	NULL
production	NULL
was	NULL
determined	NULL
by	NULL
ELISA	NULL
.	NULL

Some	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
uM	NULL
herbimycin	NULL
A	NULL
(	NULL
Herb	NULL
.	NULL

A	NULL
)	NULL
(	NULL
R	NULL
)	NULL
for	NULL
60	NULL
min	NULL
prior	NULL
to	NULL
IIC	NULL
stimulation	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
standard	NULL
deviations	NULL
.	NULL

When	NULL
not	NULL
seen	NULL
,	NULL
error	NULL
bars	NULL
are	NULL
smaller	NULL
than	NULL
the	NULL
symbols	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

overnight	NULL
culture	NULL
to	NULL
allow	NULL
for	NULL
cell	NULL
recovery	NULL
,	NULL
the	NULL
THP-1	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
various	NULL
forms	NULL
.	NULL

HA-MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
THP-1	NULL
cell	NULL
lysates	NULL
(	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
cell	NULL
equivalent	NULL
)	NULL
with	NULL
14	NULL
pg/ml	NULL
of	NULL
anti-HA	NULL
monoclonal	NULL
antibody	NULL
12CAS	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

The	NULL
antibody	NULL
was	NULL
first	NULL
incubated	NULL
with	NULL
cell	NULL
lysates	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
20	NULL
pl	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
were	NULL
added	NULL
and	NULL
the	NULL
mixture	NULL
incubated	NULL
for	NULL
another	NULL
4	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Sepharose	NULL
beads	NULL
were	NULL
then	NULL
washed	NULL
once	NULL
with	NULL
cold	NULL
RIPA	NULL
buffer	NULL
and	NULL
four	NULL
more	NULL
times	NULL
with	NULL
cold	NULL
washing	NULL
buffer	NULL
(	NULL
0.25	NULL
M	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
0.1	NULL
M	NULL
NaCl	NULL
)	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
subjected	NULL
to	NULL
a	NULL
kinase	NULL
assay	NULL
just	NULL
as	NULL
described	NULL
above	NULL
.	NULL

RESULTS	NULL
Fey	NULL
Receptor	NULL
Stimulation	NULL
Induces	NULL
Interleukin	NULL
1	NULL
Production-THP-1	NULL
monocytic	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
,	NULL
and	NULL
IL-1	NULL
produced	NULL
and	NULL
secreted	NULL
in	NULL
the	NULL
supernatant	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
commercial	NULL
ELISA	NULL
kit	NULL
.	NULL

FoyR	NULL
cross-linking	NULL
by	NULL
immune	NULL
complexes	NULL
induced	NULL
a	NULL
rapid	NULL
and	NULL
strong	NULL
production	NULL
of	NULL
IL-1	NULL
by	NULL
these	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

IL-1	NULL
production	NULL
reached	NULL
a	NULL
maximum	NULL
(	NULL
around	NULL
400	NULL
pg/ml	NULL
)	NULL
at	NULL
about	NULL
24	NULL
h	NULL
of	NULL
stimulation	NULL
.	NULL

Previous	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
the	NULL
selective	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
(	NULL
44	NULL
)	NULL
abolished	NULL
cytokine	NULL
production	NULL
,	NULL
indicating	NULL
that	NULL
FeyR-mediated	NULL
production	NULL
of	NULL
IL-1	NULL
requires	NULL
protein-tyrosine	NULL
kinase	NULL
activity	NULL
.	NULL

Fey	NULL
Receptor	NULL
Stimulation	NULL
Induces	NULL
Tyrosine	NULL
Phosphoryla-tion-Because	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
the	NULL
selective	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
(	NULL
44	NULL
)	NULL
abolished	NULL
cytokine	NULL
production	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
look	NULL
more	NULL
directly	NULL
at	NULL
the	NULL
effect	NULL
of	NULL
this	NULL
drug	NULL
on	NULL
the	NULL
FcR	NULL
response	NULL
.	NULL

Stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
caused	NULL
rapid	NULL
phosphorylation	NULL
on	NULL
tyrosine	NULL
of	NULL
several	NULL
proteins	NULL
.	NULL

Prominent	NULL
phosphotyrosine	NULL
bands	NULL
are	NULL
increased	NULL
at	NULL
1	NULL
min	NULL
of	NULL
stimulation	NULL
at	NULL
around	NULL
30	NULL
,	NULL
35	NULL
,	NULL
40	NULL
,	NULL
44	NULL
,	NULL
and	NULL
70	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
herbimycin	NULL
A	NULL
prior	NULL
to	NULL
stimulation	NULL
completely	NULL
abolished	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
these	NULL
proteins	NULL
.	NULL

Moreover	NULL
,	NULL
several	NULL
other	NULL
bands	NULL
that	NULL
were	NULL
tyrosine-phosphorylated	NULL
in	NULL
the	NULL
resting	NULL
state	NULL
also	NULL
showed	NULL
a	NULL
significant	NULL
reduction	NULL
in	NULL
presence	NULL
of	NULL
herbimycin	NULL
A	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

This	NULL
result	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
data	NULL
indicating	NULL
that	NULL
Fc	NULL
receptors	NULL
recruit	NULL
tyrosine	NULL
kinases	NULL
for	NULL
their	NULL
signaling	NULL
(	NULL
8	NULL
,	NULL
10	NULL
)	NULL
.	NULL

It	NULL
also	NULL
shows	NULL
that	NULL
herbimycin	NULL
A	NULL
is	NULL
working	NULL
well	NULL
and	NULL
it	NULL
is	NULL
blocking	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
needed	NULL
for	NULL
FoyR-mediated	NULL
IL-1	NULL
production	NULL
.	NULL

Fey	NULL
Receptor	NULL
Stimulation	NULL
Induces	NULL
Activation	NULL
of	NULL
the	NULL
Nuclear	NULL
Factor	NULL
NF-	NULL
«	NULL
B-Because	NULL
the	NULL
IL-1	NULL
gene	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
early	NULL
immediate	NULL
genes	NULL
(	NULL
such	NULL
as	NULL
those	NULL
for	NULL
IL-8	NULL
and	NULL
TNF	NULL
)	NULL
,	NULL
requires	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
for	NULL
transcriptional	NULL
acti-	NULL
FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
Blot	NULL
:	NULL
anti	NULL
-	NULL
PY	NULL
[	NULL
=	NULL
<	NULL
3	NULL
0	NULL
g	NULL
+46	NULL
$	NULL
0	NULL
0	NULL
=	NULL
9	NULL
82	NULL
kDa	NULL
46-9	NULL
war	NULL
mume	NULL
__	NULL
28	NULL
fmol	NULL
«	NULL
nge	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Fey	NULL
receptor	NULL
stimulation	NULL
induces	NULL
tyrosine	NULL
phosphory1-ation	NULL
.	NULL

1	NULL
X	NULL
10	NULL
``	NULL
THP-1	NULL
cells	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
complete	NULL
medium	NULL
were	NULL
stimulated	NULL
for	NULL
1	NULL
min	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
medium	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
40	NULL
ul	NULL
of	NULL
insoluble	NULL
immune	NULL
complexes	NULL
(	NULL
IIC	NULL
)	NULL
.	NULL

Some	NULL
cells	NULL
were	NULL
also	NULL
treated	NULL
with	NULL
10	NULL
uM	NULL
herbimycin	NULL
A	NULL
(	NULL
Herb	NULL
.	NULL

A	NULL
)	NULL
for	NULL
60	NULL
min	NULL
prior	NULL
to	NULL
IIC	NULL
stimulation	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
and	NULL
proteins	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Western	NULL
blot	NULL
for	NULL
anti-phosphotyrosines	NULL
was	NULL
done	NULL
with	NULL
5	NULL
ug/ml	NULL
monoclonal	NULL
antibody	NULL
AFT8	NULL
.	NULL

vation	NULL
(	NULL
84	NULL
,	NULL
45	NULL
)	NULL
,	NULL
we	NULL
evaluated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
FcyR	NULL
cross-linking	NULL
in	NULL
monocytes	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
reporter	NULL
plasmid	NULL
,	NULL
HIV-luc	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
cell	NULL
lysates	NULL
.	NULL

Stimulation	NULL
of	NULL
transfected	NULL
THP-1	NULL
cells	NULL
by	NULL
immune	NULL
complexes	NULL
resulted	NULL
in	NULL
a	NULL
strong	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
an	NULL
increase	NULL
(	NULL
around	NULL
4-fold	NULL
)	NULL
in	NULL
luciferase	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
herbimycin	NULL
A	NULL
also	NULL
completely	NULL
blocked	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Specificity	NULL
of	NULL
this	NULL
response	NULL
was	NULL
tested	NULL
by	NULL
transfecting	NULL
cells	NULL
with	NULL
the	NULL
plasmid	NULL
El8pal-lue	NULL
that	NULL
activates	NULL
luciferase	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
Ets	NULL
.	NULL

Stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
did	NULL
not	NULL
induce	NULL
luciferase	NULL
activity	NULL
from	NULL
this	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
15	NULL
ug/ml	NULL
lipopolysaccharide	NULL
induced	NULL
luciferase	NULL
activity	NULL
from	NULL
this	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
response	NULL
observed	NULL
after	NULL
immune	NULL
complex	NULL
stimulation	NULL
is	NULL
not	NULL
due	NULL
to	NULL
general	NULL
cell	NULL
activation	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
only	NULL
immune	NULL
complexes	NULL
were	NULL
stimulating	NULL
the	NULL
cells	NULL
via	NULL
Fc	NULL
receptors	NULL
,	NULL
transfected	NULL
THP-1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
preparations	NULL
of	NULL
antibody	NULL
and	NULL
immune	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

None	NULL
of	NULL
the	NULL
following	NULL
stimuli	NULL
caused	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
as	NULL
indicated	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
:	NULL
ferri-tin	NULL
,	NULL
the	NULL
protein	NULL
used	NULL
to	NULL
form	NULL
the	NULL
immune	NULL
complexes	NULL
,	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragments	NULL
of	NULL
the	NULL
anti-ferritin	NULL
antibodies	NULL
,	NULL
and	NULL
immune	NULL
complexes	NULL
formed	NULL
with	NULL
these	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragments	NULL
and	NULL
ferritin	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
complete	NULL
IgG	NULL
molecule	NULL
of	NULL
anti-ferritin	NULL
antibodies	NULL
caused	NULL
only	NULL
a	NULL
small	NULL
activation	NULL
,	NULL
while	NULL
the	NULL
insoluble	NULL
immune	NULL
complexes	NULL
gave	NULL
the	NULL
optimal	NULL
response	NULL
previously	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

These	NULL
data	NULL
collectively	NULL
indicate	NULL
that	NULL
FceyR	NULL
aggregation	NULL
is	NULL
responsible	NULL
for	NULL
nuclear	NULL
factor	NULL
activation	NULL
and	NULL
production	NULL
of	NULL
IL-1	NULL
,	NULL
and	NULL
that	NULL
both	NULL
events	NULL
require	NULL
protein-tyrosine	NULL
kinase	NULL
activity	NULL
to	NULL
take	NULL
place	NULL
.	NULL

FceyR-dependent	NULL
NF-	NULL
«	NULL
B	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras-There	NULL
is	NULL
evidence	NULL
that	NULL
cross-linking	NULL
of	NULL
several	NULL
immunoreceptors	NULL
in	NULL
leukocytes	NULL
activates	NULL
various	NULL
elements	NULL
of	NULL
the	NULL
Ras	NULL
con	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
M	NULL
Medium	NULL
A	NULL
c	NULL
HC	NULL
+	NULL
Herb	NULL
.	NULL

A	NULL
Luciferase	NULL
Activity	NULL
(	NULL
Fold	NULL
Increase	NULL
)	NULL
J	NULL
H	NULL
Medium	NULL
Luciferase	NULL
Activity	NULL
(	NULL
Fold	NULL
Increase	NULL
)	NULL
0	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Fey	NULL
receptor	NULL
stimulation	NULL
induces	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

A	NULL
,	NULL
3	NULL
X	NULL
10°	NULL
THP-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
reporter	NULL
plasmid	NULL
,	NULL
HIV-lue	NULL
,	NULL
were	NULL
placed	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
serum-free	NULL
medium	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
®	NULL
)	NULL
or	NULL
stimulated	NULL
by	NULL
40	NULL
ul	NULL
of	NULL
IIC	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Some	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
uM	NULL
herbimycin	NULL
A	NULL
(	NULL
§	NULL
)	NULL
for	NULL
60	NULL
min	NULL
before	NULL
IIC	NULL
stimulation	NULL
.	NULL

Five	NULL
hours	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
cell	NULL
lysates	NULL
prepared	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Luciferase	NULL
activity	NULL
,	NULL
representing	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
was	NULL
determined	NULL
in	NULL
a	NULL
luminometer	NULL
.	NULL

B	NULL
,	NULL
3	NULL
X	NULL
10°	NULL
THP-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
E18	NULL
pal-lue	NULL
reporter	NULL
plasmid	NULL
,	NULL
were	NULL
placed	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
serum-free	NULL
medium	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
@	NULL
I	NULL
)	NULL
or	NULL
stimulated	NULL
by	NULL
40	NULL
ul	NULL
of	NULL
IIC	NULL
(	NULL
2	NULL
)	NULL
or	NULL
by	NULL
15	NULL
ug/ml	NULL
lipopolysaccharide	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Five	NULL
hours	NULL
later	NULL
,	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
different	NULL
determinations	NULL
.	NULL

sensus	NULL
signaling	NULL
pathway	NULL
(	NULL
26-32	NULL
)	NULL
.	NULL

To	NULL
explore	NULL
the	NULL
possibility	NULL
that	NULL
FcyR	NULL
signaling	NULL
leading	NULL
to	NULL
nuclear	NULL
factor	NULL
activation	NULL
in	NULL
monocytic	NULL
cells	NULL
also	NULL
involved	NULL
elements	NULL
of	NULL
the	NULL
Ras	NULL
pathway	NULL
,	NULL
THP-1	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B-driven	NULL
reporter	NULL
plasmid	NULL
and	NULL
an	NULL
expression	NULL
plasmid	NULL
directing	NULL
the	NULL
synthesis	NULL
of	NULL
a	NULL
mutant	NULL
form	NULL
of	NULL
Ras	NULL
or	NULL
Raf	NULL
.	NULL

Transfected	NULL
THP-1	NULL
cells	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
evaluated	NULL
by	NULL
measuring	NULL
luciferase	NULL
activity	NULL
in	NULL
cell	NULL
lysates	NULL
.	NULL

Expression	NULL
of	NULL
either	NULL
wild-type	NULL
Ras	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
Ras	NULL
N17	NULL
did	NULL
not	NULL
affect	NULL
FoyR-mediated	NULL
NF-kB	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

That	NULL
the	NULL
mutant	NULL
Ras	NULL
proteins	NULL
were	NULL
functional	NULL
in	NULL
these	NULL
cells	NULL
was	NULL
confirmed	NULL
by	NULL
co-transfection	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
the	NULL
corresponding	NULL
Ras	NULL
construct	NULL
and	NULL
the	NULL
mitogen-responsive	NULL
reporter	NULL
system	NULL
Gal-Elk/	NULL
5XGal-lue	NULL
,	NULL
which	NULL
detects	NULL
Ras	NULL
pathway	NULL
activation	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
serum-starved	NULL
for	NULL
48	NULL
h	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
10	NULL
%	NULL
serum	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

Five	NULL
hours	NULL
after	NULL
serum	NULL
stimulation	NULL
,	NULL
a	NULL
3-fold	NULL
increase	NULL
in	NULL
Ras	NULL
activity	NULL
was	NULL
detected	NULL
by	NULL
measuring	NULL
the	NULL
luciferase	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Co-expression	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
Ras	NULL
N17	NULL
blocked	NULL
serum-induced	NULL
activation	NULL
of	NULL
the	NULL
reporter	NULL
system	NULL
to	NULL
basal	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
activated	NULL
oncogenic	NULL
Ras	NULL
L61	NULL
enhanced	NULL
the	NULL
Ras	NULL
signaling	NULL
initiated	NULL
by	NULL
serum	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
also	NULL
con	NULL
27613	NULL
B	NULL
Medium	NULL
47	NULL
A	NULL
c	NULL
M	NULL
19s	NULL
on	NULL
A	NULL
F	NULL
(	NULL
ab	NULL
``	NULL
)	NULL
2	NULL
az	NULL
31	NULL
3	NULL
E	NULL
;	NULL
C	NULL
Ag	NULL
<	NULL
$	NULL
M	NULL
F	NULL
(	NULL
ab	NULL
)	NULL
2+	NULL
Ag	NULL
6	NULL
I	NULL
£	NULL
[	NULL
od	NULL
-	NULL
G	NULL
£	NULL
6	NULL
``	NULL
o	NULL
&	NULL
.	NULL

3	NULL
``	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Immune	NULL
complex	NULL
stimulation	NULL
is	NULL
mediated	NULL
by	NULL
Fey	NULL
receptors	NULL
.	NULL

3	NULL
X	NULL
10°	NULL
THP-1	NULL
cells	NULL
,	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-kB	NULL
reporter	NULL
plasmid	NULL
,	NULL
HIV-lue	NULL
,	NULL
were	NULL
placed	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
serum-free	NULL
medium	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
®	NULL
or	NULL
stimulated	NULL
by	NULL
40	NULL
ul	NULL
of	NULL
IIC	NULL
(	NULL
2	NULL
)	NULL
,	NULL
by	NULL
anti-ferritin	NULL
IgG	NULL
(	NULL
©	NULL
)	NULL
,	NULL
by	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
2	NULL
fragments	NULL
of	NULL
this	NULL
anti-ferritin	NULL
antibody	NULL
(	NULL
M	NULL
)	NULL
,	NULL
by	NULL
ferritin	NULL
(	NULL
)	NULL
)	NULL
,	NULL
or	NULL
by	NULL
immune	NULL
complexes	NULL
formed	NULL
with	NULL
ferritin	NULL
and	NULL
the	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragments	NULL
of	NULL
this	NULL
anti-ferritin	NULL
antibody	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Five	NULL
hours	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
cell	NULL
lysates	NULL
prepared	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Luciferase	NULL
activity	NULL
,	NULL
representing	NULL
NF-KB	NULL
activation	NULL
,	NULL
was	NULL
determined	NULL
in	NULL
a	NULL
luminometer	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
different	NULL
determinations	NULL
.	NULL

firmed	NULL
that	NULL
,	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
the	NULL
mutant	NULL
forms	NULL
of	NULL
Ras	NULL
were	NULL
affecting	NULL
Ras	NULL
signaling	NULL
activity	NULL
as	NULL
expected	NULL
.	NULL

After	NULL
Ras	NULL
activation	NULL
,	NULL
the	NULL
serine-threonine	NULL
kinase	NULL
Raf	NULL
is	NULL
the	NULL
next	NULL
element	NULL
in	NULL
the	NULL
Ras	NULL
signaling	NULL
pathway	NULL
(	NULL
20	NULL
,	NULL
46	NULL
)	NULL
.	NULL

To	NULL
explore	NULL
if	NULL
this	NULL
kinase	NULL
was	NULL
involved	NULL
in	NULL
FcyR	NULL
signaling	NULL
in	NULL
monocytes	NULL
,	NULL
THP-1	NULL
cells	NULL
were	NULL
also	NULL
co-transfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
reporter	NULL
plasmid	NULL
and	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
form	NULL
of	NULL
Raf-1	NULL
,	NULL
Raf	NULL
23-284	NULL
.	NULL

Expression	NULL
of	NULL
this	NULL
altered	NULL
protein	NULL
did	NULL
not	NULL
prevent	NULL
NF-kB	NULL
activation	NULL
by	NULL
insoluble	NULL
immune	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Control	NULL
experiments	NULL
using	NULL
serum	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
mitogen-responsive	NULL
reporter	NULL
system	NULL
Gal-Elk/5XGal-luc	NULL
indicated	NULL
that	NULL
Raf	NULL
23-284	NULL
can	NULL
efficiently	NULL
block	NULL
serum-mediated	NULL
activation	NULL
of	NULL
the	NULL
Ras	NULL
pathway	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
Ras	NULL
and	NULL
Raf	NULL
are	NULL
not	NULL
directly	NULL
involved	NULL
in	NULL
the	NULL
FcoyR-mediated	NULL
signal	NULL
transduction	NULL
pathway	NULL
in	NULL
monocytic	NULL
cells	NULL
that	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

In	NULL
order	NULL
to	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
these	NULL
results	NULL
were	NULL
only	NULL
valid	NULL
on	NULL
the	NULL
THP-1	NULL
cell	NULL
line	NULL
used	NULL
,	NULL
the	NULL
experiments	NULL
were	NULL
repeated	NULL
in	NULL
another	NULL
monocytic	NULL
cell	NULL
line	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B-driven	NULL
reporter	NULL
plasmid	NULL
and	NULL
also	NULL
with	NULL
the	NULL
dominant	NULL
negative	NULL
mutants	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Similarly	NULL
to	NULL
previous	NULL
results	NULL
,	NULL
stimulation	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
resulted	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-KB	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
dominant	NULL
negative	NULL
forms	NULL
Ras	NULL
N17	NULL
,	NULL
and	NULL
Raf	NULL
23-284	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
,	NULL
supporting	NULL
the	NULL
previous	NULL
data	NULL
that	NULL
FcR-mediated	NULL
signaling	NULL
for	NULL
activation	NULL
of	NULL
genes	NULL
does	NULL
not	NULL
involve	NULL
the	NULL
proteins	NULL
Ras	NULL
and	NULL
Raf	NULL
.	NULL

Data	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
also	NULL
indicated	NULL
that	NULL
this	NULL
results	NULL
are	NULL
valid	NULL
for	NULL
several	NULL
monocytic	NULL
cell	NULL
lines	NULL
.	NULL

FceyR-mediated	NULL
NF-kB	NULL
Activation	NULL
Requires	NULL
MEK	NULL
Activa-tion-Although	NULL
Ras	NULL
and	NULL
Raf	NULL
did	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
many	NULL
reports	NULL
have	NULL
indicated	NULL
that	NULL
MAPK	NULL
is	NULL
activated	NULL
after	NULL
cross-linking	NULL
of	NULL
FoeyR	NULL
.	NULL

MEK	NULL
is	NULL
a	NULL
cytoplasmic	NULL
serine-threonine	NULL
kinase	NULL
that	NULL
directly	NULL
activates	NULL
MAPK	NULL
by	NULL
phosphorylating	NULL
its	NULL
TEY	NULL
domain	NULL
on	NULL
threo-nine	NULL
and	NULL
tyrosine	NULL
residues	NULL
(	NULL
47	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
MEK	NULL
was	NULL
participating	NULL
in	NULL
FoeyR	NULL
signaling	NULL
leading	NULL
to	NULL
nuclear	NULL
factor	NULL
activation	NULL
,	NULL
we	NULL
used	NULL
the	NULL
selective	NULL
MEK	NULL
inhibitor	NULL
PD98059	NULL
,	NULL
in	NULL
THP-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-kB	NULL
reporter	NULL
plasmid	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
PD98059	NULL
for	NULL
60	NULL
min	NULL
before	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27614	NULL
A	NULL
M	NULL
Medium	NULL
5	NULL
A	NULL
ic	NULL
€	NULL
soles	NULL
>	NULL
ao	NULL
4	NULL
*	NULL
{	NULL
o	NULL
<	NULL
C	NULL
2	NULL
os	NULL
6	NULL
o	NULL
5	NULL
w	NULL
su	NULL
?	NULL

£	NULL
&	NULL
o	NULL
S	NULL
1	NULL
fer	NULL
D	NULL
+	NULL
pZIP	NULL
Ras	NULL
N17	NULL
B	NULL
M	NULL
Nvedium	NULL
CQ	NULL
Serum	NULL
6	NULL
>	NULL
brad	NULL
=	NULL
L200	NULL
5	NULL
*	NULL
f	NULL
0	NULL
<	NULL
4	NULL
$	NULL
o	NULL
4	NULL
i	NULL
.	NULL

2	NULL
o	NULL
C	NULL
i	NULL
3	NULL
©	NULL
3	NULL
©	NULL
6	NULL
2200	NULL
?	NULL

3	NULL
34	NULL
1	NULL
i	NULL
;	NULL
0	NULL
pZIP	NULL
Ras	NULL
N17	NULL
Ras	NULL
61L	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

FeyR-dependent	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
is	NULL
independent	NULL
of	NULL
Ras	NULL
.	NULL

A	NULL
,	NULL
3	NULL
X	NULL
10°	NULL
THP-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-xB	NULL
reporter	NULL
plasmid	NULL
,	NULL
HIV-luc	NULL
,	NULL
were	NULL
placed	NULL
in	NULL
serum-free	NULL
medium	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
®	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
co-transfected	NULL
with	NULL
the	NULL
vector	NULL
pZIP	NULL
or	NULL
with	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
form	NULL
of	NULL
Ras	NULL
N17	NULL
cloned	NULL
into	NULL
pZIP	NULL
.	NULL

Luciferase	NULL
activity	NULL
,	NULL
representing	NULL
NF-kB	NULL
activation	NULL
,	NULL
was	NULL
determined	NULL
5	NULL
h	NULL
later	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
*	NULL
S.E	NULL
.	NULL

of	NULL
eight	NULL
different	NULL
determinations	NULL
.	NULL

B	NULL
,	NULL
THP-1	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
the	NULL
Ras-reporter	NULL
system	NULL
Gal-Elk/5XGal-luc	NULL
,	NULL
and	NULL
pZIP	NULL
,	NULL
Ras	NULL
N17	NULL
,	NULL
or	NULL
the	NULL
activated	NULL
oncogenic	NULL
form	NULL
of	NULL
Ras	NULL
L61	NULL
.	NULL

After	NULL
transfection	NULL
cells	NULL
were	NULL
serum-starved	NULL
for	NULL
48	NULL
h	NULL
and	NULL
then	NULL
left	NULL
untreated	NULL
(	NULL
@	NULL
I	NULL
or	NULL
stimulated	NULL
with	NULL
10	NULL
%	NULL
serum	NULL
(	NULL
&	NULL
)	NULL
.	NULL

Luciferase	NULL
activity	NULL
,	NULL
indicating	NULL
Ras	NULL
pathway	NULL
activation	NULL
,	NULL
was	NULL
determined	NULL
5	NULL
h	NULL
later	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
different	NULL
determinations	NULL
.	NULL

stimulation	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
resulted	NULL
in	NULL
complete	NULL
inhibition	NULL
of	NULL
FcyR-mediated	NULL
NF-KB	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

This	NULL
result	NULL
clearly	NULL
showed	NULL
the	NULL
participation	NULL
of	NULL
MEK	NULL
in	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
from	NULL
Fc	NULL
receptors	NULL
leading	NULL
to	NULL
activation	NULL
of	NULL
this	NULL
nuclear	NULL
factor	NULL
.	NULL

Also	NULL
,	NULL
PD98059	NULL
affected	NULL
the	NULL
production	NULL
of	NULL
IL-1	NULL
by	NULL
these	NULL
cells	NULL
after	NULL
IIC	NULL
stimulation	NULL
.	NULL

However	NULL
,	NULL
a	NULL
concentration	NULL
of	NULL
PD98059	NULL
that	NULL
completely	NULL
blocked	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
inhibited	NULL
IL-1	NULL
production	NULL
only	NULL
about	NULL
40	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Increasing	NULL
concentrations	NULL
of	NULL
the	NULL
MEK	NULL
inhibitor	NULL
did	NULL
not	NULL
further	NULL
block	NULL
IL-1	NULL
production	NULL
.	NULL

FcyR	NULL
Stimulation	NULL
by	NULL
Insoluble	NULL
Immune	NULL
Complexes	NULL
Results	NULL
in	NULL
MAPK	NULL
Activation-Our	NULL
results	NULL
,	NULL
described	NULL
above	NULL
,	NULL
indicated	NULL
that	NULL
FcyR	NULL
signaling	NULL
in	NULL
monocytic	NULL
cells	NULL
did	NULL
not	NULL
involve	NULL
Ras	NULL
and	NULL
Raf	NULL
,	NULL
but	NULL
clearly	NULL
activated	NULL
MEK	NULL
and	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-kB	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
MAPK	NULL
was	NULL
connecting	NULL
MEK	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
look	NULL
directly	NULL
at	NULL
MAPK	NULL
activation	NULL
by	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
.	NULL

Stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
IIC	NULL
resulted	NULL
in	NULL
a	NULL
clear	NULL
and	NULL
strong	NULL
stimulation	NULL
of	NULL
MAPK	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
FeyR-mediated	NULL
activation	NULL
of	NULL
MAPK	NULL
showed	NULL
maximal	NULL
kinase	NULL
activity	NULL
by	NULL
1	NULL
min	NULL
of	NULL
IIC	NULL
stimulation	NULL
.	NULL

This	NULL
activity	NULL
had	NULL
returned	NULL
to	NULL
basal	NULL
levels	NULL
around	NULL
3	NULL
min	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

This	NULL
result	NULL
was	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
reports	NULL
that	NULL
FoyR	NULL
cross-link	NULL
,	NULL
ing	NULL
results	NULL
in	NULL
MAPK	NULL
activation	NULL
.	NULL

Moreover	NULL
,	NULL
treatment	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
PD98059	NULL
for	NULL
1	NULL
h	NULL
before	NULL
IIC	NULL
stimulation	NULL
demonstrated	NULL
FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
A	NULL
B	NULL
Medium	NULL
IIC	NULL
3	NULL
6	NULL
>	NULL
L	NULL
B2	NULL
i	NULL
g.	NULL
2	NULL
w	NULL
8	NULL
4	NULL
F	NULL
$	NULL
€	NULL
s	NULL
E	NULL
3	NULL
£	NULL
p	NULL
C	NULL
0	NULL
_-8	NULL
1	NULL
M	NULL
o	NULL
pCGN	NULL
Raf	NULL
23-284	NULL
B	NULL
B	NULL
Nedium	NULL
5	NULL
C	NULL
Serum	NULL
I2	NULL
3	NULL
_	NULL
=	NULL
©	NULL
4	NULL
o	NULL
<	NULL
$	NULL
Se	NULL
o	NULL
C	NULL
p	NULL
&	NULL
©	NULL
B	NULL
2	NULL
€	NULL
2	NULL
°	NULL
1	NULL
-j_	NULL
‘	NULL
;	NULL
-I	NULL
0	NULL
pCGN	NULL
Raf	NULL
23-284	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

FeyR-dependent	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
is	NULL
independent	NULL
of	NULL
Raf	NULL
.	NULL

A	NULL
,	NULL
3	NULL
X	NULL
10°	NULL
THP-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-xB	NULL
reporter	NULL
plasmid	NULL
,	NULL
HIV-luc	NULL
,	NULL
were	NULL
placed	NULL
in	NULL
serum-free	NULL
medium	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
®	NULL
)	NULL
or	NULL
stimulated	NULL
by	NULL
insoluble	NULL
immune	NULL
complexes	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
co-transfected	NULL
with	NULL
the	NULL
vector	NULL
pCGN	NULL
or	NULL
with	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
form	NULL
of	NULL
Raf	NULL
23-284	NULL
cloned	NULL
into	NULL
pCGN	NULL
.	NULL

Luciferase	NULL
activity	NULL
,	NULL
representing	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
was	NULL
determined	NULL
5	NULL
h	NULL
later	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
five	NULL
different	NULL
determinations	NULL
.	NULL

B	NULL
,	NULL
THP-1	NULL
cells	NULL
co-transfected	NULL
with	NULL
the	NULL
Ras	NULL
reporter	NULL
system	NULL
Gal-EIk/5XGal-lue	NULL
,	NULL
and	NULL
pCGN	NULL
,	NULL
or	NULL
Raf	NULL
23-284	NULL
,	NULL
were	NULL
serum-starved	NULL
for	NULL
48	NULL
h	NULL
and	NULL
then	NULL
left	NULL
untreated	NULL
(	NULL
RI	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
10	NULL
%	NULL
serum	NULL
(	NULL
§	NULL
)	NULL
.	NULL

Luciferase	NULL
activity	NULL
,	NULL
indicating	NULL
Ras	NULL
pathway	NULL
activation	NULL
,	NULL
was	NULL
determined	NULL
5	NULL
h	NULL
later	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
different	NULL
determinations	NULL
.	NULL

that	NULL
FcoyR-mediated	NULL
MAPK	NULL
activation	NULL
is	NULL
completely	NULL
blocked	NULL
when	NULL
MEK	NULL
activation	NULL
is	NULL
inhibited	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggested	NULL
that	NULL
,	NULL
in	NULL
FcyR	NULL
signaling	NULL
,	NULL
MEK	NULL
activation	NULL
is	NULL
an	NULL
upstream	NULL
event	NULL
of	NULL
MAP	NULL
kinase	NULL
activation	NULL
,	NULL
which	NULL
then	NULL
leads	NULL
to	NULL
nuclear	NULL
factor	NULL
NF-KB	NULL
activation	NULL
.	NULL

FceyR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras-Data	NULL
presented	NULL
above	NULL
indicated	NULL
that	NULL
MAPK	NULL
is	NULL
clearly	NULL
activated	NULL
by	NULL
insoluble	NULL
immune	NULL
complexes	NULL
and	NULL
that	NULL
the	NULL
Ras	NULL
and	NULL
Raf	NULL
dominant	NULL
negative	NULL
constructs	NULL
did	NULL
not	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

It	NULL
was	NULL
then	NULL
important	NULL
to	NULL
determine	NULL
directly	NULL
if	NULL
these	NULL
dominant	NULL
negative	NULL
mutants	NULL
did	NULL
not	NULL
blocked	NULL
FcyR-dependent	NULL
MAPK	NULL
activation	NULL
.	NULL

It	NULL
is	NULL
not	NULL
easy	NULL
to	NULL
see	NULL
the	NULL
effect	NULL
of	NULL
these	NULL
mutants	NULL
on	NULL
MAPK	NULL
directly	NULL
because	NULL
the	NULL
efficiency	NULL
of	NULL
transfection	NULL
of	NULL
monocytic	NULL
cells	NULL
is	NULL
rather	NULL
low	NULL
,	NULL
approximately	NULL
5	NULL
%	NULL
,	NULL
as	NULL
estimated	NULL
by	NULL
transfections	NULL
with	NULL
a	NULL
plasmid	NULL
that	NULL
expresses	NULL
the	NULL
GFP	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
constructs	NULL
is	NULL
only	NULL
on	NULL
those	NULL
cells	NULL
that	NULL
were	NULL
successfully	NULL
transfected	NULL
.	NULL

To	NULL
test	NULL
for	NULL
the	NULL
effect	NULL
of	NULL
these	NULL
negative	NULL
mutants	NULL
on	NULL
MAPK	NULL
activity	NULL
of	NULL
only	NULL
transfected	NULL
cells	NULL
,	NULL
THP-1	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
a	NULL
MAPK	NULL
that	NULL
has	NULL
the	NULL
HA	NULL
epitope	NULL
tag	NULL
and	NULL
the	NULL
corresponding	NULL
Ras	NULL
N17	NULL
or	NULL
Raf	NULL
23-284	NULL
dominant	NULL
negative	NULL
mu-tants	NULL
.	NULL

After	NULL
transfection	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
and	NULL
cell	NULL
lysates	NULL
prepared	NULL
.	NULL

HA-MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
these	NULL
lysates	NULL
with	NULL
the	NULL
HA-specific	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
4	NULL
B	NULL
Medium	NULL
r	NULL
?	NULL

G	NULL
c	NULL
2	NULL
37	NULL
=	NULL
C	NULL
0	NULL
<	NULL
&	NULL
d	NULL
i	NULL
o	NULL
€	NULL
a	NULL
21	NULL
e	NULL
]	NULL
3	NULL
C	NULL
0	NULL
_-3	NULL
_I	NULL
14	NULL
o	NULL
pZIP	NULL
Ras	NULL
N17	NULL
pCGN	NULL
-	NULL
Raf	NULL
23-284	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

The	NULL
monocytic	NULL
cell	NULL
line	NULL
U937	NULL
also	NULL
presents	NULL
FeyR-dependent	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
independent	NULL
of	NULL
Ras	NULL
.	NULL

3	NULL
X	NULL
10°	NULL
U937	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
reporter	NULL
plasmid	NULL
,	NULL
HIV-luc	NULL
,	NULL
were	NULL
placed	NULL
in	NULL
serum-free	NULL
medium	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
@	NULL
I	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
co-transfected	NULL
with	NULL
the	NULL
vector	NULL
pZIP	NULL
or	NULL
with	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
form	NULL
of	NULL
Ras	NULL
N17	NULL
cloned	NULL
into	NULL
pZIP	NULL
,	NULL
and	NULL
with	NULL
the	NULL
vector	NULL
pCGN	NULL
or	NULL
with	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
form	NULL
of	NULL
Raf	NULL
28-284	NULL
cloned	NULL
into	NULL
pCGN	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
determined	NULL
5	NULL
h	NULL
later	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
different	NULL
determinations	NULL
.	NULL

B	NULL
Medium	NULL
IC	NULL
4	NULL
C	NULL
nc	NULL
+PDasosg	NULL
3	NULL
l	NULL
—7	NULL
1	NULL
0	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

FeyR-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
requires	NULL
MEK	NULL
activation	NULL
.	NULL

THP-1	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
NF-KB	NULL
reporter	NULL
plasmid	NULL
,	NULL
HIV-lue	NULL
,	NULL
were	NULL
placed	NULL
in	NULL
serum-free	NULL
medium	NULL
and	NULL
left	NULL
untreated	NULL
(	NULL
RD	NULL
or	NULL
stimulated	NULL
by	NULL
insoluble	NULL
immune	NULL
complexes	NULL
(	NULL
2	NULL
)	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
30	NULL
uM	NULL
PD98059	NULL
(	NULL
&	NULL
)	NULL
for	NULL
60	NULL
min	NULL
before	NULL
IIC	NULL
stimulation	NULL
.	NULL

Five	NULL
hours	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
cell	NULL
lysates	NULL
prepared	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Luciferase	NULL
activity	NULL
,	NULL
representing	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
was	NULL
determined	NULL
in	NULL
a	NULL
luminometer	NULL
.	NULL

Data	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
three	NULL
determinations	NULL
.	NULL

Activity	NULL
(	NULL
Fold	NULL
Increase	NULL
)	NULL
N	NULL
Luciferase	NULL
monoclonal	NULL
antibody	NULL
12CA5	NULL
,	NULL
and	NULL
its	NULL
activity	NULL
tested	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
Ras	NULL
N17	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
kinase	NULL
activity	NULL
stimulated	NULL
by	NULL
FeyR	NULL
cross-linking	NULL
with	NULL
immune	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

12A	NULL
)	NULL
.	NULL

Control	NULL
experiments	NULL
using	NULL
serum	NULL
stimulation	NULL
of	NULL
transfected	NULL
THP-1	NULL
cells	NULL
indicated	NULL
that	NULL
Ras	NULL
N17	NULL
could	NULL
block	NULL
MAPK	NULL
activation	NULL
induced	NULL
by	NULL
a	NULL
different	NULL
stimulus	NULL
(	NULL
Fig	NULL
.	NULL

120	NULL
)	NULL
.	NULL

In	NULL
a	NULL
similar	NULL
fashion	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
Raf	NULL
23-284	NULL
dominant	NULL
negative	NULL
mutant	NULL
on	NULL
HA-MAPK	NULL
activation	NULL
after	NULL
transfected	NULL
THP-1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
insoluble	NULL
immune	NULL
complexes	NULL
.	NULL

Expression	NULL
of	NULL
this	NULL
mutant	NULL
did	NULL
not	NULL
inhibit	NULL
FeyR-dependent	NULL
activation	NULL
of	NULL
MAPK	NULL
(	NULL
Fig	NULL
.	NULL

134	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
efficacy	NULL
of	NULL
this	NULL
negative	NULL
constructs	NULL
,	NULL
transfected	NULL
THP-1	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
serum	NULL
and	NULL
HA-MAPK	NULL
activity	NULL
measured	NULL
in	NULL
an	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
.	NULL

Similarly	NULL
to	NULL
previous	NULL
results	NULL
,	NULL
Raf	NULL
23-284	NULL
inhibited	NULL
activation	NULL
of	NULL
MAPK	NULL
induced	NULL
by	NULL
serum	NULL
(	NULL
Fig	NULL
.	NULL

13C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
all	NULL
together	NULL
support	NULL
the	NULL
idea	NULL
that	NULL
FceyR	NULL
signaling	NULL
does	NULL
not	NULL
use	NULL
Ras	NULL
or	NULL
Raf	NULL
to	NULL
activate	NULL
MEK	NULL
and	NULL
MAPK	NULL
in	NULL
the	NULL
pathway	NULL
that	NULL
leads	NULL
to	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

27615	NULL
e	NULL
...	NULL
...	NULL
&	NULL
~~~	NULL
_	NULL
IIC	NULL
+	NULL
PD98059	NULL
--	NULL
O-	NULL
_	NULL
Medium	NULL
490	NULL
E	NULL
-	NULL
390	NULL
€	NULL
&	NULL
&	NULL
-	NULL
290	NULL
T	NULL
-	NULL
190	NULL
-	NULL
!	NULL

90	NULL
-o	NULL
'10|	NULL
I	NULL
I	NULL
I	NULL
I	NULL
0	NULL
8	NULL
16	NULL
2	NULL
4	NULL
3	NULL
2	NULL
4	NULL
0	NULL
4	NULL
8	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

MEK	NULL
activity	NULL
is	NULL
needed	NULL
for	NULL
FeyR-mediated	NULL
IL-1	NULL
production	NULL
.	NULL

1	NULL
X	NULL
10°	NULL
THP-1	NULL
cells	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
complete	NULL
medium	NULL
were	NULL
incubated	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
medium	NULL
)	NULL
(	NULL
0	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
40	NULL
ul	NULL
of	NULL
IIC	NULL
(	NULL
@	NULL
)	NULL
.	NULL

IL-1	NULL
production	NULL
was	NULL
determined	NULL
by	NULL
ELISA	NULL
.	NULL

Some	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
30	NULL
um	NULL
PD98059	NULL
(	NULL
&	NULL
)	NULL
for	NULL
60	NULL
min	NULL
prior	NULL
to	NULL
IIC	NULL
stimulation	NULL
.	NULL

Error	NULL
bars	NULL
represent	NULL
standard	NULL
deviations	NULL
.	NULL

When	NULL
not	NULL
seen	NULL
,	NULL
error	NULL
bars	NULL
are	NULL
smaller	NULL
than	NULL
the	NULL
symbols	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

A	NULL
IP	NULL
:	NULL
anti-MAPK	NULL
0	NULL
1	NULL
3	NULL
5	NULL
min	NULL
<	NULL
a	NULL
»	NULL
Tl	NULL
stow	NULL
«	NULL
<	NULL
a	NULL
»	NULL
=	NULL
B	NULL
--	NULL
MAPK	NULL
Blot	NULL
:	NULL
anti-MAPK	NULL
Fig	NULL
.	NULL

10	NULL
.	NULL

Kinetics	NULL
of	NULL
MAPK	NULL
activation	NULL
after	NULL
Fey	NULL
receptor	NULL
cross-linking	NULL
with	NULL
IIC	NULL
.	NULL

1.5	NULL
x	NULL
10	NULL
``	NULL
THP-1	NULL
cells	NULL
in	NULL
7.5	NULL
ml	NULL
of	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
were	NULL
stimulated	NULL
with	NULL
60	NULL
ul	NULL
of	NULL
IIC	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

MAPK	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
from	NULL
cell	NULL
lysates	NULL
.	NULL

A	NULL
,	NULL
MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
equal	NULL
number	NULL
of	NULL
cells	NULL
with	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
,	NULL
and	NULL
its	NULL
kinase	NULL
activity	NULL
determined	NULL
by	NULL
myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
)	NULL
phosphorylation	NULL
.	NULL

Following	NULL
separation	NULL
of	NULL
the	NULL
substrate	NULL
(	NULL
MBP	NULL
)	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
the	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

B	NULL
,	NULL
Western	NULL
blot	NULL
of	NULL
MAPK	NULL
using	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
showing	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
immunoprecipitated	NULL
in	NULL
each	NULL
determination	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

DISCUSSION	NULL
Membrane	NULL
receptors	NULL
for	NULL
the	NULL
Fc	NULL
portion	NULL
of	NULL
immunoglobulin	NULL
G	NULL
class	NULL
antibodies	NULL
(	NULL
FcyR	NULL
)	NULL
are	NULL
expressed	NULL
on	NULL
almost	NULL
every	NULL
type	NULL
of	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Cross-linking	NULL
of	NULL
these	NULL
receptors	NULL
by	NULL
aggregated	NULL
IgG	NULL
,	NULL
in	NULL
the	NULL
form	NULL
of	NULL
antigen-antibody	NULL
complexes	NULL
,	NULL
triggers	NULL
a	NULL
very	NULL
wide	NULL
array	NULL
of	NULL
responses	NULL
important	NULL
for	NULL
host	NULL
defense	NULL
and	NULL
for	NULL
modulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
3	NULL
)	NULL
.	NULL

There	NULL
is	NULL
a	NULL
great	NULL
deal	NULL
of	NULL
interest	NULL
in	NULL
understanding	NULL
the	NULL
signaling	NULL
mechanisms	NULL
that	NULL
lead	NULL
to	NULL
the	NULL
various	NULL
cell	NULL
responses	NULL
.	NULL

One	NULL
of	NULL
the	NULL
most	NULL
important	NULL
functions	NULL
activated	NULL
by	NULL
immune	NULL
complexes	NULL
on	NULL
myelomonocytic	NULL
and	NULL
NK	NULL
cells	NULL
is	NULL
the	NULL
production	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
such	NULL
as	NULL
IL-1	NULL
,	NULL
IL-8	NULL
,	NULL
and	NULL
TNF	NULL
.	NULL

This	NULL
means	NULL
that	NULL
FcyR	NULL
cross-linking	NULL
induces	NULL
transcription	NULL
of	NULL
the	NULL
genes	NULL
encoding	NULL
these	NULL
response	NULL
(	NULL
2	NULL
,	NULL
18	NULL
)	NULL
.	NULL

To	NULL
have	NULL
initiation	NULL
of	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
,	NULL
activation	NULL
of	NULL
diverse	NULL
nuclear	NULL
factors	NULL
has	NULL
to	NULL
take	NULL
place	NULL
.	NULL

Very	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
from	NULL
FeyR	NULL
to	NULL
nuclear	NULL
factors	NULL
in	NULL
the	NULL
cell	NULL
nucleus	NULL
.	NULL

It	NULL
has	NULL
been	NULL
observed	NULL
that	NULL
the	NULL
5	NULL
'	NULL
regulatory	NULL
sequences	NULL
of	NULL
the	NULL
cytokine	NULL
genes	NULL
induced	NULL
by	NULL
FcyR	NULL
cross-linking	NULL
(	NULL
IL-1	NULL
,	NULL
IL-8	NULL
,	NULL
TNF	NULL
)	NULL
,	NULL
all	NULL
contain	NULL
sites	NULL
for	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
84-36	NULL
)	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
reasoned	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
would	NULL
be	NULL
an	NULL
ideal	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27616	NULL
A	NULL
IP	NULL
:	NULL
anti-MAPK	NULL
Control	NULL
IIC	NULL
IIC	NULL
+	NULL
PD98059	NULL
mms	NULL
,	NULL
.._	NULL
--	NULL
MBP	NULL
B	NULL
G-	NULL
<	NULL
»	NULL
MD	NULL
Blot	NULL
:	NULL
anti-MAPK	NULL
Fig	NULL
.	NULL

11	NULL
.	NULL

FeyR-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
requires	NULL
MEK	NULL
activation	NULL
.	NULL

THP-1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
30	NULL
uM	NULL
of	NULL
the	NULL
selective	NULL
MEK	NULL
inhibitor	NULL
PD98059	NULL
for	NULL
60	NULL
min	NULL
before	NULL
IIC	NULL
stimulation	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

10	NULL
,	NULL
during	NULL
1	NULL
min	NULL
and	NULL
then	NULL
cell	NULL
lysates	NULL
prepared	NULL
and	NULL
MAPK	NULL
activity	NULL
determined	NULL
by	NULL
immune	NULL
complex	NULL
kinase	NULL
assay	NULL
.	NULL

A	NULL
,	NULL
MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
equal	NULL
number	NULL
of	NULL
cells	NULL
with	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
,	NULL
and	NULL
its	NULL
kinase	NULL
activity	NULL
determined	NULL
by	NULL
MBP	NULL
phosphorylation	NULL
.	NULL

B	NULL
,	NULL
Western	NULL
blot	NULL
of	NULL
MAPK	NULL
using	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
showing	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
immunoprecipitated	NULL
in	NULL
each	NULL
determination	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

-a-	NULL
MAPK	NULL
way	NULL
for	NULL
monitoring	NULL
the	NULL
FcyR	NULL
signaling	NULL
pathway	NULL
leading	NULL
to	NULL
gene	NULL
induction	NULL
.	NULL

We	NULL
decided	NULL
to	NULL
investigate	NULL
directly	NULL
if	NULL
FeyR	NULL
cross-linking	NULL
on	NULL
THP-1	NULL
monocytic	NULL
cells	NULL
also	NULL
resulted	NULL
in	NULL
production	NULL
of	NULL
IL-1	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Insoluble	NULL
immune	NULL
complexes	NULL
indeed	NULL
caused	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
luciferase	NULL
production	NULL
from	NULL
the	NULL
NF-	NULL
«	NULL
B-specific	NULL
reporter	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
response	NULL
is	NULL
clearly	NULL
mediated	NULL
by	NULL
Fc	NULL
receptors	NULL
because	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
;	NULL
fragments	NULL
of	NULL
antibodies	NULL
or	NULL
antibody	NULL
complexes	NULL
made	NULL
with	NULL
them	NULL
,	NULL
were	NULL
unable	NULL
to	NULL
stimulate	NULL
the	NULL
NF-	NULL
«	NULL
B-specific	NULL
reporter	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

So	NULL
,	NULL
FeyR	NULL
stimulation	NULL
in	NULL
monocytic	NULL
cells	NULL
initiates	NULL
a	NULL
signal	NULL
transduction	NULL
pathway	NULL
that	NULL
activates	NULL
nuclear	NULL
factors	NULL
and	NULL
induces	NULL
IL-1	NULL
gene	NULL
expression	NULL
.	NULL

FcyR	NULL
,	NULL
and	NULL
also	NULL
the	NULL
antigen	NULL
receptors	NULL
on	NULL
T	NULL
lymphocytes	NULL
and	NULL
B	NULL
lymphocytes	NULL
,	NULL
present	NULL
a	NULL
common	NULL
feature	NULL
that	NULL
is	NULL
important	NULL
for	NULL
signaling	NULL
by	NULL
all	NULL
these	NULL
immunoreceptors	NULL
(	NULL
5	NULL
)	NULL
.	NULL

They	NULL
all	NULL
contain	NULL
a	NULL
conserved	NULL
motif	NULL
,	NULL
known	NULL
as	NULL
ITAM	NULL
for	NULL
immunoreceptor	NULL
tyrosine-based	NULL
activation	NULL
motif	NULL
(	NULL
7	NULL
,	NULL
9	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
phosphorylation	NULL
sites	NULL
important	NULL
for	NULL
signal	NULL
transduction	NULL
.	NULL

Polyvalent	NULL
ligands	NULL
induce	NULL
receptor	NULL
cross-linking	NULL
and	NULL
activation	NULL
of	NULL
Src	NULL
family	NULL
(	NULL
48	NULL
,	NULL
49	NULL
)	NULL
and	NULL
Syk/ZAP-70	NULL
family	NULL
related	NULL
kinases	NULL
(	NULL
50-52	NULL
)	NULL
,	NULL
which	NULL
associate	NULL
with	NULL
the	NULL
phosphorylated	NULL
ITAM	NULL
in	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
the	NULL
receptor	NULL
.	NULL

After	NULL
FoyR	NULL
aggregation	NULL
,	NULL
these	NULL
activated	NULL
kinases	NULL
catalyze	NULL
the	NULL
phosphorylation	NULL
of	NULL
cellular	NULL
substrates	NULL
on	NULL
tyrosine	NULL
residues	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
(	NULL
10	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
nature	NULL
of	NULL
these	NULL
substrates	NULL
and	NULL
other	NULL
molecules	NULL
involved	NULL
in	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
is	NULL
not	NULL
clearly	NULL
identified	NULL
.	NULL

Activation	NULL
of	NULL
tyrosine	NULL
kinases	NULL
leading	NULL
finally	NULL
to	NULL
nuclear	NULL
factor	NULL
activation	NULL
resembles	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
defined	NULL
for	NULL
receptor	NULL
tyrosine	NULL
kinases	NULL
that	NULL
induces	NULL
mitogenic	NULL
signals	NULL
in	NULL
response	NULL
to	NULL
growth	NULL
factors	NULL
such	NULL
as	NULL
epidermal	NULL
growth	NULL
factor	NULL
and	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
.	NULL

This	NULL
signaling	NULL
pathway	NULL
is	NULL
also	NULL
known	NULL
as	NULL
the	NULL
Ras	NULL
pathway	NULL
(	NULL
20	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Receptor	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
induces	NULL
transient	NULL
formation	NULL
of	NULL
Ras-GTP	NULL
and	NULL
activation	NULL
of	NULL
Raf	NULL
kinase	NULL
at	NULL
the	NULL
membrane	NULL
,	NULL
followed	NULL
by	NULL
sequential	NULL
activation	NULL
of	NULL
MEK	NULL
and	NULL
MAPK	NULL
(	NULL
22	NULL
)	NULL
.	NULL

MAPK	NULL
is	NULL
then	NULL
responsible	NULL
for	NULL
activation	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
has	NULL
been	NULL
thought	NULL
that	NULL
the	NULL
classical	NULL
Ras	NULL
signal	NULL
transduction	NULL
pathway	NULL
(	NULL
37	NULL
)	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
FeyR	NULL
signaling	NULL
leading	NULL
to	NULL
activation	NULL
of	NULL
nuclear	NULL
factors	NULL
and	NULL
cytokine	NULL
production	NULL
.	NULL

FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
pZIP	NULL
pZIP	NULL
+	NULL
HC	NULL
Ras	NULL
N17	NULL
+	NULL
IIC	NULL
A	NULL
IP	NULL
:	NULL
anti-HA-MAPK	NULL
A	NULL
'	NULL
«	NULL
we	NULL
-4	NULL
--	NULL
MBP	NULL
B	NULL
Blot	NULL
:	NULL
anti-MAPK	NULL
llis	NULL
:	NULL
was	NULL
-a-	NULL
MAPK	NULL
a	NULL
+8	NULL
}	NULL
§	NULL
4	NULL
&	NULL
5	NULL
T5	NULL
4A	NULL
gw	NULL
o	NULL
o+	NULL
C	NULL
IP	NULL
:	NULL
anti-HA-MAPK	NULL
______	NULL
«	NULL
e	NULL
MBP	NULL
D	NULL
Blot	NULL
:	NULL
anti-MAPK	NULL
-	NULL
ee	NULL
``	NULL
Fic	NULL
.	NULL

12	NULL
.	NULL

Ras	NULL
N17	NULL
does	NULL
not	NULL
inhibit	NULL
MAPK	NULL
activation	NULL
after	NULL
Fey	NULL
receptor	NULL
cross-linking	NULL
.	NULL

1.5	NULL
X	NULL
10	NULL
``	NULL
THP-1	NULL
cells	NULL
,	NULL
co-transfected	NULL
with	NULL
HA-MAPK	NULL
and	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
Ras	NULL
N17	NULL
or	NULL
the	NULL
empty	NULL
vector	NULL
pZIP	NULL
,	NULL
were	NULL
stimulated	NULL
with	NULL
60	NULL
pl	NULL
of	NULL
IIC	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
with	NULL
serum	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
for	NULL
1	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

MAPK	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
from	NULL
cell	NULL
lysates	NULL
.	NULL

A	NULL
,	NULL
HA-MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
equal	NULL
number	NULL
of	NULL
IIC-stimulated	NULL
cells	NULL
with	NULL
anti-HA	NULL
monoclonal	NULL
antibody	NULL
,	NULL
12CAS5	NULL
,	NULL
and	NULL
its	NULL
kinase	NULL
activity	NULL
determined	NULL
by	NULL
MBP	NULL
phosphorylation	NULL
.	NULL

Following	NULL
separation	NULL
of	NULL
the	NULL
substrate	NULL
(	NULL
MBP	NULL
)	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
the	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

B	NULL
,	NULL
Western	NULL
blot	NULL
of	NULL
MAPK	NULL
using	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
showing	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
immunoprecipitated	NULL
in	NULL
each	NULL
determination	NULL
from	NULL
A	NULL
.	NULL

C	NULL
,	NULL
HA-MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
equal	NULL
number	NULL
of	NULL
serum-stimulated	NULL
cells	NULL
with	NULL
anti-HA	NULL
monoclonal	NULL
antibody	NULL
,	NULL
12CA5	NULL
,	NULL
and	NULL
its	NULL
kinase	NULL
activity	NULL
determined	NULL
by	NULL
MBP	NULL
phosphorylation	NULL
.	NULL

D	NULL
,	NULL
Western	NULL
blot	NULL
of	NULL
MAPK	NULL
using	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
showing	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
immunoprecipitated	NULL
in	NULL
each	NULL
determination	NULL
from	NULL
C.	NULL
Data	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
.	NULL

Moreover	NULL
,	NULL
recent	NULL
reports	NULL
indicate	NULL
that	NULL
MAPK	NULL
is	NULL
activated	NULL
after	NULL
FoyR	NULL
cross-linking	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
26-32	NULL
)	NULL
,	NULL
supporting	NULL
the	NULL
idea	NULL
that	NULL
the	NULL
Ras	NULL
pathway	NULL
is	NULL
used	NULL
by	NULL
FcyR	NULL
to	NULL
induce	NULL
gene	NULL
transcription	NULL
.	NULL

However	NULL
,	NULL
no	NULL
direct	NULL
evidence	NULL
of	NULL
Ras	NULL
involvement	NULL
has	NULL
been	NULL
provided	NULL
in	NULL
these	NULL
reports	NULL
.	NULL

A	NULL
recent	NULL
publication	NULL
indicates	NULL
that	NULL
an	NULL
increase	NULL
in	NULL
Ras-GTP	NULL
was	NULL
observed	NULL
after	NULL
cross-linking	NULL
of	NULL
FeyRIIIA	NULL
on	NULL
NK	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
,	NULL
further	NULL
supporting	NULL
the	NULL
idea	NULL
for	NULL
FcyR	NULL
using	NULL
the	NULL
Ras	NULL
signaling	NULL
pathway	NULL
.	NULL

Because	NULL
MAPK	NULL
activation	NULL
does	NULL
not	NULL
necessarily	NULL
mean	NULL
that	NULL
the	NULL
Ras	NULL
pathway	NULL
is	NULL
being	NULL
utilized	NULL
,	NULL
and	NULL
because	NULL
diverse	NULL
signaling	NULL
pathways	NULL
may	NULL
be	NULL
used	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
,	NULL
a	NULL
direct	NULL
evaluation	NULL
for	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
various	NULL
elements	NULL
of	NULL
the	NULL
Ras	NULL
pathway	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
becomes	NULL
important	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
participation	NULL
of	NULL
the	NULL
Ras	NULL
signaling	NULL
pathway	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
cytokine	NULL
genes	NULL
upon	NULL
FcyR	NULL
cross-linking	NULL
on	NULL
monocytes	NULL
,	NULL
probing	NULL
for	NULL
the	NULL
different	NULL
elements	NULL
involved	NULL
in	NULL
this	NULL
signaling	NULL
cascade	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
Ras	NULL
signal	NULL
pathway	NULL
elements	NULL
in	NULL
the	NULL
FoyR	NULL
signal	NULL
transduction	NULL
pathway	NULL
was	NULL
investigated	NULL
by	NULL
measuring	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
pCen	NULL
z	NULL
fed	NULL
4	NULL
+	NULL
IIC	NULL
Raf	NULL
23-284	NULL
+	NULL
IIC	NULL
A	NULL
IP	NULL
:	NULL
anti-HA-MAPK	NULL
--	NULL
-	NULL
MBP	NULL
B	NULL
Blot	NULL
:	NULL
anti-MAPK	NULL
``	NULL
a	NULL
«	NULL
--	NULL
MAPK	NULL
2	NULL
&	NULL
2	NULL
.	NULL

C	NULL
IP	NULL
:	NULL
anti-HA-MAPK	NULL
D	NULL
Blot	NULL
:	NULL
anti-MAPK	NULL
«	NULL
a	NULL
em	NULL
am	NULL
)	NULL
--	NULL
*	NULL
Fic	NULL
.	NULL

13	NULL
.	NULL

Raf	NULL
23-284	NULL
does	NULL
not	NULL
inhibit	NULL
MAPK	NULL
activation	NULL
after	NULL
Fey	NULL
receptor	NULL
cross-linking	NULL
.	NULL

1.5	NULL
X	NULL
10	NULL
``	NULL
THP-1	NULL
cells	NULL
,	NULL
co-transfected	NULL
with	NULL
HA-MAPK	NULL
and	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
Raf	NULL
28-284	NULL
or	NULL
the	NULL
empty	NULL
vector	NULL
pCGN	NULL
,	NULL
were	NULL
stimulated	NULL
with	NULL
60	NULL
ul	NULL
of	NULL
IC	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
with	NULL
serum	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
for	NULL
1	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

MAPK	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
immune	NULL
complex	NULL
kinase	NULL
assays	NULL
from	NULL
cell	NULL
lysates	NULL
.	NULL

A	NULL
,	NULL
HA-MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
equal	NULL
number	NULL
of	NULL
IIC-stimulated	NULL
cells	NULL
with	NULL
anti-HA	NULL
monoclonal	NULL
antibody	NULL
,	NULL
12CAS5	NULL
,	NULL
and	NULL
its	NULL
kinase	NULL
activity	NULL
determined	NULL
by	NULL
MBP	NULL
phosphorylation	NULL
.	NULL

Following	NULL
separation	NULL
of	NULL
the	NULL
substrate	NULL
(	NULL
MBP	NULL
)	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
the	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

B	NULL
,	NULL
Western	NULL
blot	NULL
of	NULL
MAPK	NULL
using	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
showing	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
immunoprecipitated	NULL
in	NULL
each	NULL
determination	NULL
from	NULL
A	NULL
.	NULL

C	NULL
,	NULL
HA-MAPK	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
equal	NULL
number	NULL
of	NULL
serum-stimulated	NULL
cells	NULL
with	NULL
anti-HA	NULL
monoclonal	NULL
antibody	NULL
,	NULL
12CA5	NULL
,	NULL
and	NULL
its	NULL
kinase	NULL
activity	NULL
determined	NULL
by	NULL
MBP	NULL
phosphorylation	NULL
.	NULL

D	NULL
,	NULL
Western	NULL
blot	NULL
of	NULL
MAPK	NULL
using	NULL
anti-pan	NULL
ERK	NULL
monoclonal	NULL
antibody	NULL
showing	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
protein	NULL
immunoprecipitated	NULL
in	NULL
each	NULL
determination	NULL
from	NULL
C.	NULL
Data	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
.	NULL

pCGN	NULL
+	NULL
Serum	NULL
Raf	NULL
23-284	NULL
+	NULL
Serum	NULL
-==	NULL
MBP	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
specific	NULL
inhibitors	NULL
.	NULL

Expression	NULL
of	NULL
either	NULL
wild-type	NULL
Ras	NULL
or	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
Ras	NULL
N17	NULL
,	NULL
in	NULL
THP-1	NULL
cells	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
FcoyR-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Similarly	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
mutant	NULL
form	NULL
of	NULL
Raf-1	NULL
,	NULL
Raf	NULL
23-284	NULL
,	NULL
did	NULL
not	NULL
prevent	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
insoluble	NULL
immune	NULL
complexes	NULL
.	NULL

These	NULL
mutants	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
efficiently	NULL
block	NULL
signal	NULL
transduction	NULL
via	NULL
the	NULL
classical	NULL
Ras	NULL
pathway	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
(	NULL
see	NULL
also	NULL
Figs	NULL
.	NULL

5B	NULL
and	NULL
6B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
the	NULL
monocytic	NULL
cell	NULL
line	NULL
THP-1	NULL
.	NULL

In	NULL
order	NULL
to	NULL
confirm	NULL
that	NULL
this	NULL
was	NULL
a	NULL
more	NULL
general	NULL
behavior	NULL
of	NULL
monocytes	NULL
,	NULL
the	NULL
experiments	NULL
were	NULL
repeated	NULL
in	NULL
a	NULL
different	NULL
monocytic	NULL
cell	NULL
line	NULL
.	NULL

Data	NULL
on	NULL
U9837	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
also	NULL
showed	NULL
that	NULL
dominant	NULL
negative	NULL
mutant	NULL
forms	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
immune	NULL
complexes	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
monocytic	NULL
cells	NULL
,	NULL
Ras	NULL
and	NULL
Raf	NULL
are	NULL
not	NULL
directly	NULL
involved	NULL
in	NULL
the	NULL
FoyR-mediated	NULL
signal	NULL
transduction	NULL
path	NULL
27617	NULL
way	NULL
that	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
NF-kB	NULL
.	NULL

Although	NULL
Ras	NULL
and	NULL
Raf	NULL
did	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
many	NULL
reports	NULL
have	NULL
indicated	NULL
that	NULL
MAPK	NULL
is	NULL
activated	NULL
after	NULL
cross-linking	NULL
of	NULL
FcyR	NULL
,	NULL
so	NULL
downstream	NULL
elements	NULL
in	NULL
the	NULL
Ras	NULL
pathway	NULL
may	NULL
still	NULL
be	NULL
used	NULL
for	NULL
FceyR	NULL
signaling	NULL
.	NULL

MEK	NULL
is	NULL
a	NULL
cytoplasmic	NULL
serine-threonine	NULL
kinase	NULL
that	NULL
directly	NULL
activates	NULL
MAPK	NULL
(	NULL
47	NULL
)	NULL
and	NULL
it	NULL
is	NULL
found	NULL
downstream	NULL
of	NULL
Raf	NULL
in	NULL
the	NULL
Ras	NULL
signaling	NULL
cascade	NULL
activated	NULL
by	NULL
receptor	NULL
tyrosine	NULL
kinases	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
selective	NULL
MEK	NULL
inhibitor	NULL
,	NULL
PD98059	NULL
,	NULL
completely	NULL
blocked	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
indicating	NULL
that	NULL
MEK	NULL
participated	NULL
in	NULL
FcyR-mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Immune	NULL
complex	NULL
stimulation	NULL
of	NULL
THP-1	NULL
cells	NULL
also	NULL
resulted	NULL
in	NULL
activation	NULL
of	NULL
MAPK	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
using	NULL
MBP	NULL
as	NULL
substrate	NULL
for	NULL
the	NULL
kinase	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
PD98059	NULL
was	NULL
able	NULL
to	NULL
block	NULL
MAPK	NULL
activation	NULL
back	NULL
to	NULL
basal	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
.	NULL

This	NULL
established	NULL
a	NULL
link	NULL
between	NULL
FcyR	NULL
and	NULL
the	NULL
pathway	NULL
MEK	NULL
,	NULL
MAPK	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
kB	NULL
.	NULL

Moreover	NULL
,	NULL
evaluating	NULL
directly	NULL
MAPK	NULL
activity	NULL
only	NULL
in	NULL
transfected	NULL
cells	NULL
by	NULL
using	NULL
the	NULL
HA-MAPK	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
the	NULL
dominant	NULL
negative	NULL
mutants	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
did	NULL
not	NULL
affect	NULL
FceyR-dependent	NULL
activation	NULL
of	NULL
this	NULL
kinase	NULL
(	NULL
Figs	NULL
.	NULL

12	NULL
and	NULL
13	NULL
)	NULL
.	NULL

These	NULL
data	NULL
further	NULL
supported	NULL
the	NULL
idea	NULL
that	NULL
FoyR	NULL
cross-linking	NULL
activates	NULL
a	NULL
MAPK	NULL
pathway	NULL
without	NULL
using	NULL
the	NULL
proteins	NULL
Ras	NULL
and	NULL
Raf	NULL
.	NULL

Treatment	NULL
of	NULL
THP-1	NULL
cells	NULL
with	NULL
a	NULL
concentration	NULL
of	NULL
PD98059	NULL
that	NULL
completely	NULL
blocked	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
resulted	NULL
only	NULL
in	NULL
partial	NULL
inhibition	NULL
of	NULL
IL-1	NULL
production	NULL
.	NULL

To	NULL
initiate	NULL
transcription	NULL
of	NULL
the	NULL
IL-1	NULL
gene	NULL
,	NULL
more	NULL
than	NULL
one	NULL
nuclear	NULL
factor	NULL
is	NULL
required	NULL
.	NULL

The	NULL
promoter	NULL
region	NULL
of	NULL
this	NULL
and	NULL
many	NULL
other	NULL
genes	NULL
contains	NULL
multiple	NULL
and	NULL
different	NULL
sites	NULL
for	NULL
nuclear	NULL
factor	NULL
binding	NULL
(	NULL
36	NULL
,	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
one	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
identified	NULL
to	NULL
bind	NULL
at	NULL
the	NULL
5	NULL
'	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
IL-1	NULL
gene	NULL
(	NULL
84-86	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
blockage	NULL
of	NULL
MEK	NULL
and	NULL
MAPK	NULL
activity	NULL
by	NULL
the	NULL
inhibitor	NULL
PD98059	NULL
resulted	NULL
in	NULL
failure	NULL
to	NULL
activate	NULL
NF-kB	NULL
,	NULL
and	NULL
therefore	NULL
reduced	NULL
FcyR-mediated	NULL
IL-1	NULL
production	NULL
in	NULL
monocytes	NULL
.	NULL

Full	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-1	NULL
gene	NULL
needs	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
cooperation	NULL
from	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
36	NULL
,	NULL
53	NULL
,	NULL
54	NULL
)	NULL
.	NULL

This	NULL
cooperation	NULL
effect	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
the	NULL
THP-1	NULL
cells	NULL
for	NULL
the	NULL
IL-8	NULL
gene	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
monocytic	NULL
cells	NULL
was	NULL
done	NULL
with	NULL
immune	NULL
complexes	NULL
.	NULL

These	NULL
interact	NULL
and	NULL
stimulate	NULL
all	NULL
types	NULL
of	NULL
Fc	NULL
receptors	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
known	NULL
that	NULL
the	NULL
various	NULL
types	NULL
of	NULL
Fc	NULL
receptors	NULL
activate	NULL
different	NULL
cellular	NULL
responses	NULL
(	NULL
1	NULL
,	NULL
3	NULL
,	NULL
55	NULL
)	NULL
,	NULL
so	NULL
it	NULL
would	NULL
be	NULL
very	NULL
interesting	NULL
to	NULL
know	NULL
what	NULL
type	NULL
of	NULL
receptor	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
MAPK	NULL
and	NULL
nuclear	NULL
factor	NULL
activations	NULL
that	NULL
are	NULL
connected	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
monocytes	NULL
.	NULL

We	NULL
are	NULL
now	NULL
investigating	NULL
this	NULL
by	NULL
stimulating	NULL
cells	NULL
with	NULL
the	NULL
monoclonal	NULL
antibodies	NULL
IV.3	NULL
and	NULL
3G8	NULL
,	NULL
which	NULL
are	NULL
specific	NULL
for	NULL
FcyRII	NULL
and	NULL
FcyRIII	NULL
,	NULL
respectively	NULL
.	NULL

Our	NULL
preliminary	NULL
results	NULL
indicate	NULL
that	NULL
both	NULL
receptors	NULL
FcyRII	NULL
and	NULL
FcyRIII	NULL
,	NULL
expressed	NULL
on	NULL
monocytic	NULL
cells	NULL
,	NULL
are	NULL
capable	NULL
of	NULL
inducing	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
although	NULL
they	NULL
seem	NULL
to	NULL
do	NULL
it	NULL
at	NULL
lower	NULL
levels	NULL
compared	NULL
with	NULL
immune	NULL
complex	NULL
stimulation	NULL
.	NULL

How	NULL
MEK	NULL
is	NULL
activated	NULL
without	NULL
Raf	NULL
participation	NULL
is	NULL
not	NULL
clear	NULL
,	NULL
but	NULL
there	NULL
is	NULL
evidence	NULL
for	NULL
diverse	NULL
ways	NULL
to	NULL
activate	NULL
this	NULL
kinase	NULL
(	NULL
56	NULL
)	NULL
.	NULL

MEK	NULL
is	NULL
phosphorylated	NULL
and	NULL
activated	NULL
by	NULL
an	NULL
upstream	NULL
kinase	NULL
,	NULL
which	NULL
in	NULL
the	NULL
case	NULL
of	NULL
many	NULL
serum	NULL
growth	NULL
factor	NULL
receptors	NULL
is	NULL
the	NULL
proto-oncogene	NULL
Raf	NULL
.	NULL

Direct	NULL
action	NULL
of	NULL
Raf	NULL
over	NULL
MEK	NULL
is	NULL
clearly	NULL
established	NULL
(	NULL
57	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Another	NULL
MEK	NULL
kinase	NULL
,	NULL
also	NULL
called	NULL
MEKK	NULL
,	NULL
has	NULL
been	NULL
described	NULL
upstream	NULL
of	NULL
MEK	NULL
in	NULL
the	NULL
signaling	NULL
pathway	NULL
from	NULL
a	NULL
different	NULL
type	NULL
of	NULL
receptors	NULL
(	NULL
56	NULL
)	NULL
.	NULL

MEKK	NULL
is	NULL
the	NULL
mammalian	NULL
counterpart	NULL
of	NULL
the	NULL
yeast	NULL
protein	NULL
kinases	NULL
Byr2	NULL
(	NULL
from	NULL
Schizosaccharomyces	NULL
pombe	NULL
)	NULL
and	NULL
Stell	NULL
(	NULL
from	NULL
Saccharo-myces	NULL
cerevisiae	NULL
)	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
activate	NULL
the	NULL
protein	NULL
kinases	NULL
Byrl1	NULL
and	NULL
Ste7	NULL
,	NULL
respectively	NULL
.	NULL

Byrl	NULL
and	NULL
Ste7	NULL
have	NULL
considerably	NULL
sequence	NULL
homology	NULL
to	NULL
MEK	NULL
and	NULL
function	NULL
in	NULL
the	NULL
pheromone-induced	NULL
signaling	NULL
pathway	NULL
that	NULL
leads	NULL
to	NULL
mating	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Some	NULL
pheromone	NULL
receptors	NULL
have	NULL
a	NULL
seven-membrane-spanning	NULL
ser-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27618	NULL
Aggregated	NULL
Foy	NULL
R	NULL
yp	NULL
YR	NULL
ayy	NULL
t	NULL
?	NULL

t	NULL
MEK	NULL
u	NULL
MAPK	NULL
u	NULL
NF-	NULL
«	NULL
B	NULL
Fic	NULL
.	NULL

14	NULL
.	NULL

Model	NULL
for	NULL
FeyR-mediated	NULL
signal	NULL
transduction	NULL
in	NULL
monocytic	NULL
THP-1	NULL
cells	NULL
.	NULL

FoyR	NULL
are	NULL
aggregated	NULL
by	NULL
immune	NULL
complexes	NULL
formed	NULL
by	NULL
IgG	NULL
bound	NULL
to	NULL
polyvalent	NULL
antigens	NULL
.	NULL

Tyrosine	NULL
kinases	NULL
,	NULL
such	NULL
as	NULL
Syk	NULL
,	NULL
are	NULL
activated	NULL
and	NULL
bound	NULL
to	NULL
the	NULL
tyrosine-phosphorylated	NULL
receptor	NULL
.	NULL

Direct	NULL
substrates	NULL
for	NULL
these	NULL
tyrosine	NULL
kinases	NULL
are	NULL
not	NULL
clearly	NULL
defined	NULL
.	NULL

The	NULL
signaling	NULL
pathway	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
MEK	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
phosphorylates	NULL
and	NULL
activates	NULL
MAPK	NULL
.	NULL

These	NULL
enzymes	NULL
are	NULL
then	NULL
responsible	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-B	NULL
.	NULL

There	NULL
is	NULL
not	NULL
involvement	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
proteins	NULL
upstream	NULL
of	NULL
MEK	NULL
.	NULL

pentine	NULL
structure	NULL
coupled	NULL
to	NULL
G	NULL
proteins	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
mammalian	NULL
cells	NULL
,	NULL
some	NULL
serpentine	NULL
receptors	NULL
coupled	NULL
to	NULL
heterotrimeric	NULL
G	NULL
;	NULL
,	NULL
proteins	NULL
can	NULL
stimulate	NULL
DNA	NULL
synthesis	NULL
via	NULL
MAPK	NULL
activation	NULL
(	NULL
59	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
G	NULL
;	NULL
,	NULL
-coupled	NULL
acetylcholine	NULL
muscarinic	NULL
M2	NULL
receptors	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
activate	NULL
MEK	NULL
and	NULL
MAPK	NULL
independently	NULL
of	NULL
Raf	NULL
.	NULL

The	NULL
kinase	NULL
responsible	NULL
for	NULL
this	NULL
effect	NULL
is	NULL
MEKK	NULL
(	NULL
59	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
mouse	NULL
(	NULL
NIH3T3	NULL
)	NULL
and	NULL
rat	NULL
(	NULL
Ratla	NULL
)	NULL
fibroblasts	NULL
,	NULL
MEK	NULL
and	NULL
MAPK	NULL
are	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
recognized	NULL
by	NULL
a	NULL
receptor	NULL
tyrosine	NULL
kinase	NULL
)	NULL
and	NULL
also	NULL
in	NULL
response	NULL
to	NULL
thrombin	NULL
(	NULL
recognized	NULL
by	NULL
a	NULL
serpentine	NULL
G	NULL
protein-coupled	NULL
receptor	NULL
)	NULL
.	NULL

Raf	NULL
is	NULL
activated	NULL
by	NULL
epidermal	NULL
growth	NULL
factor	NULL
but	NULL
not	NULL
thrombin	NULL
(	NULL
60	NULL
)	NULL
.	NULL

It	NULL
seems	NULL
,	NULL
then	NULL
,	NULL
that	NULL
MEKK	NULL
is	NULL
a	NULL
conserved	NULL
kinase	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
G	NULL
protein-coupled	NULL
signal	NULL
pathways	NULL
in	NULL
yeast	NULL
and	NULL
vertebrates	NULL
and	NULL
Raf	NULL
represents	NULL
a	NULL
divergence	NULL
in	NULL
vertebrates	NULL
from	NULL
the	NULL
yeast	NULL
pheromone-responsive	NULL
protein	NULL
kinase	NULL
system	NULL
(	NULL
59	NULL
,	NULL
61	NULL
)	NULL
.	NULL

Whether	NULL
G	NULL
protein	NULL
subunits	NULL
activate	NULL
MEKK	NULL
directly	NULL
or	NULL
through	NULL
an	NULL
unknown	NULL
intermediary	NULL
molecule	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
(	NULL
61	NULL
)	NULL
.	NULL

FcyR	NULL
are	NULL
not	NULL
associated	NULL
with	NULL
G	NULL
proteins	NULL
.	NULL

The	NULL
kinase	NULL
responsible	NULL
for	NULL
MEK	NULL
activation	NULL
after	NULL
immune	NULL
complexes	NULL
stimulation	NULL
remains	NULL
unknown	NULL
.	NULL

Because	NULL
G	NULL
proteins	NULL
may	NULL
activate	NULL
MEKK	NULL
indirectly	NULL
,	NULL
it	NULL
may	NULL
be	NULL
possible	NULL
that	NULL
this	NULL
kinase	NULL
is	NULL
also	NULL
used	NULL
by	NULL
FcyR	NULL
to	NULL
activate	NULL
MEK	NULL
.	NULL

Another	NULL
possibility	NULL
is	NULL
that	NULL
FoyR	NULL
may	NULL
activate	NULL
MEK	NULL
via	NULL
a	NULL
different	NULL
and	NULL
yet	NULL
undescribed	NULL
kinase	NULL
that	NULL
has	NULL
MEK	NULL
kinase	NULL
properties	NULL
.	NULL

It	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
the	NULL
involvement	NULL
of	NULL
MEKK	NULL
in	NULL
FeyR	NULL
signaling	NULL
to	NULL
the	NULL
nucleus	NULL
to	NULL
activate	NULL
gene	NULL
transcription	NULL
.	NULL

FcyR	NULL
signaling	NULL
initiates	NULL
with	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Herbimycin	NULL
A	NULL
,	NULL
a	NULL
selective	NULL
inhibitor	NULL
of	NULL
tyrosine	NULL
kinases	NULL
,	NULL
completely	NULL
blocked	NULL
both	NULL
IL-1	NULL
production	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-driven	NULL
reporter	NULL
plasmid	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
,	NULL
confirming	NULL
that	NULL
FceyR	NULL
aggregation	NULL
triggers	NULL
activation	NULL
of	NULL
tyrosine	NULL
kinases	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
as	NULL
an	NULL
early	NULL
event	NULL
in	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
from	NULL
Fc	NULL
receptors	NULL
to	NULL
gene	NULL
activation	NULL
and	NULL
production	NULL
of	NULL
cytokines	NULL
in	NULL
monocytes	NULL
.	NULL

Syk	NULL
kinase	NULL
(	NULL
72	NULL
kDa	NULL
)	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
FcyR	NULL
signaling	NULL
in	NULL
several	NULL
cell	NULL
types	NULL
.	NULL

Syk	NULL
belongs	NULL
to	NULL
the	NULL
ZAP-70	NULL
kinase	NULL
family	NULL
.	NULL

These	NULL
enzymes	NULL
are	NULL
not	NULL
myristoylated	NULL
and	NULL
therefore	NULL
are	NULL
exclusively	NULL
cytoplasmic	NULL
.	NULL

Syk	NULL
is	NULL
present	NULL
in	NULL
all	NULL
hematopoietic	NULL
cells	NULL
,	NULL
whereas	NULL
ZAP-70	NULL
is	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
NK	NULL
cells	NULL
(	NULL
62	NULL
)	NULL
.	NULL

In	NULL
mast	NULL
cells	NULL
(	NULL
RBL-2H3	NULL
)	NULL
,	NULL
MAPK	NULL
FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
activation	NULL
has	NULL
been	NULL
clearly	NULL
shown	NULL
to	NULL
by	NULL
dependent	NULL
of	NULL
Syk	NULL
,	NULL
probably	NULL
through	NULL
the	NULL
GTP/GDP	NULL
exchange	NULL
factor	NULL
Vav	NULL
(	NULL
63	NULL
)	NULL
.	NULL

The	NULL
link	NULL
between	NULL
FceR	NULL
and	NULL
MAPK	NULL
may	NULL
also	NULL
be	NULL
through	NULL
She	NULL
,	NULL
which	NULL
is	NULL
phosphorylated	NULL
by	NULL
Syk	NULL
and	NULL
then	NULL
binds	NULL
to	NULL
Grb2	NULL
.	NULL

This	NULL
adaptor	NULL
protein	NULL
is	NULL
known	NULL
to	NULL
associate	NULL
with	NULL
Sos	NULL
to	NULL
activate	NULL
Ras	NULL
upstream	NULL
of	NULL
MAPK	NULL
(	NULL
64	NULL
)	NULL
,	NULL
although	NULL
in	NULL
mast	NULL
cells	NULL
the	NULL
FeeR	NULL
for	NULL
IgE	NULL
seems	NULL
to	NULL
connect	NULL
Syk	NULL
to	NULL
MAPK	NULL
via	NULL
Ras	NULL
.	NULL

In	NULL
monocytes	NULL
,	NULL
we	NULL
did	NULL
not	NULL
find	NULL
evidence	NULL
for	NULL
Ras	NULL
or	NULL
Raf	NULL
involvement	NULL
in	NULL
MEK	NULL
and	NULL
MAPK	NULL
activation	NULL
after	NULL
FoyR	NULL
cross-linking	NULL
.	NULL

Syk	NULL
is	NULL
the	NULL
most	NULL
likely	NULL
tyrosine	NULL
kinase	NULL
involved	NULL
in	NULL
FeyR	NULL
signal	NULL
transduction	NULL
in	NULL
THP-1	NULL
monocytic	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
did	NULL
not	NULL
look	NULL
directly	NULL
at	NULL
Syk	NULL
,	NULL
but	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
confirm	NULL
that	NULL
Syk	NULL
activation	NULL
is	NULL
required	NULL
for	NULL
MEK	NULL
and	NULL
MAPK	NULL
activation	NULL
in	NULL
THP-1	NULL
cells	NULL
.	NULL

The	NULL
mechanism	NULL
that	NULL
Syk	NULL
may	NULL
use	NULL
to	NULL
activate	NULL
this	NULL
downstream	NULL
kinases	NULL
bypassing	NULL
Ras	NULL
and	NULL
Raf	NULL
is	NULL
unknown	NULL
,	NULL
but	NULL
as	NULL
discussed	NULL
above	NULL
,	NULL
it	NULL
may	NULL
be	NULL
through	NULL
activation	NULL
of	NULL
MEKK	NULL
.	NULL

As	NULL
of	NULL
this	NULL
report	NULL
,	NULL
there	NULL
are	NULL
no	NULL
studies	NULL
directly	NULL
looking	NULL
for	NULL
a	NULL
functional	NULL
interaction	NULL
between	NULL
Syk	NULL
and	NULL
MEKK	NULL
in	NULL
any	NULL
cell	NULL
type	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
work	NULL
strongly	NULL
suggest	NULL
that	NULL
the	NULL
monocyte	NULL
signaling	NULL
pathway	NULL
from	NULL
Fc	NULL
receptors	NULL
leading	NULL
to	NULL
expression	NULL
of	NULL
different	NULL
genes	NULL
important	NULL
to	NULL
leukocyte	NULL
biology	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
,	NULL
initiates	NULL
with	NULL
tyrosine	NULL
kinases	NULL
and	NULL
requires	NULL
MAPK	NULL
activation	NULL
,	NULL
but	NULL
in	NULL
contrast	NULL
to	NULL
other	NULL
tyrosine	NULL
kinase	NULL
receptors	NULL
,	NULL
FcyR-mediated	NULL
MAPK	NULL
activation	NULL
does	NULL
not	NULL
involve	NULL
Ras	NULL
and	NULL
Raf	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
John	NULL
Westwick	NULL
and	NULL
Dr.	NULL
David	NULL
A.	NULL
Brenner	NULL
(	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
NC	NULL
)	NULL
for	NULL
generously	NULL
donating	NULL
the	NULL
HIV-lue	NULL
and	NULL
the	NULL
E18pal-lue	NULL
plasmids	NULL
,	NULL
and	NULL
Dr.	NULL
Mike	NULL
Weber	NULL
(	NULL
University	NULL
of	NULL
Virginia	NULL
,	NULL
Charlottesville	NULL
,	NULL
VA	NULL
)	NULL
for	NULL
the	NULL
HA-MAPK	NULL
.	NULL

We	NULL
specially	NULL
thank	NULL
Dr.	NULL
Channing	NULL
Der	NULL
(	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
NC	NULL
)	NULL
for	NULL
donating	NULL
all	NULL
normal	NULL
or	NULL
mutant	NULL
forms	NULL
of	NULL
Ras	NULL
and	NULL
Raf	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Michelle	NULL
Soriano	NULL
Lesh	NULL
for	NULL
purifying	NULL
the	NULL
anti-phosphotyrosine	NULL
monoclonal	NULL
antibody	NULL
AFT8	NULL
,	NULL
and	NULL
Nancy	NULL
Mora	NULL
Pérez	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Unkeless	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Boros	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Fein	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
in	NULL
Inflammation	NULL
:	NULL
Basic	NULL
Principles	NULL
and	NULL
Clinical	NULL
Correlates	NULL
(	NULL
Gallin	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
Goldstein	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
and	NULL
Snyderman	NULL
,	NULL
R.	NULL
,	NULL
eds	NULL
)	NULL
2nd	NULL
Ed	NULL
.	NULL

,	NULL
pp	NULL
.	NULL

497-510	NULL
,	NULL
Raven	NULL
Press	NULL
,	NULL
Ltd.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Van	NULL
de	NULL
Winkel	NULL
,	NULL
J.	NULL
G.	NULL
J.	NULL
,	NULL
and	NULL
Capel	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
14	NULL
,	NULL
215-221	NULL
.	NULL

Sanchez-Mejorada	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Rosales	NULL
,	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

63	NULL
,	NULL
521-533	NULL
.	NULL

Ravetch	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
and	NULL
Kinet	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

9	NULL
,	NULL
457-492	NULL
.	NULL

Keegan	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
Paul	NULL
,	NULL
W.	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
18	NULL
,	NULL
63-68	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Littman	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
263-274	NULL
Cambier	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

155	NULL
,	NULL
3281-8285	NULL
.	NULL

Cambier	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunol	NULL
.	NULL

Left	NULL
.	NULL

44	NULL
,	NULL
77-80	NULL
.	NULL

Isakov	NULL
,	NULL
N.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

61	NULL
,	NULL
6-16	NULL
.	NULL

Santana	NULL
,	NULL
C.	NULL
,	NULL
Noris	NULL
,	NULL
G.	NULL
,	NULL
Espinoza	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Ortega	NULL
,	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

60	NULL
,	NULL
433-440	NULL
11	NULL
.	NULL

Azzoni	NULL
,	NULL
L.	NULL
,	NULL
Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Salcedo	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
Kanakaraj	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Perussia	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176	NULL
,	NULL
1745-1750	NULL
12	NULL
.	NULL

Ting	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Karnitz	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Schoon	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Abraham	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
and	NULL
Leibson	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176	NULL
,	NULL
1751-1755	NULL
13	NULL
.	NULL

Liao	NULL
,	NULL
F.	NULL
,	NULL
Shin	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
and	NULL
Rhee	NULL
,	NULL
S.	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
3659-3663	NULL
14	NULL
.	NULL

Shen	NULL
,	NULL
Z.	NULL
,	NULL
Lin	NULL
,	NULL
C.-T.	NULL
,	NULL
and	NULL
Unkeless	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

152	NULL
,	NULL
3017-8028	NULL
15	NULL
.	NULL

Ninoyima	NULL
,	NULL
N.	NULL
,	NULL
Hazeki	NULL
,	NULL
K.	NULL
,	NULL
Fukui	NULL
,	NULL
Y.	NULL
,	NULL
Seya	NULL
,	NULL
T.	NULL
,	NULL
Okada	NULL
,	NULL
T.	NULL
,	NULL
Hazeki	NULL
,	NULL
O.	NULL
,	NULL
and	NULL
Ui	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
22732-22737	NULL
16	NULL
.	NULL

Kanakaraj	NULL
,	NULL
P.	NULL
,	NULL
Duckworth	NULL
,	NULL
B.	NULL
,	NULL
Azzoni	NULL
,	NULL
L.	NULL
,	NULL
Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Cantley	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
and	NULL
Perussia	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179	NULL
,	NULL
551-558	NULL
17	NULL
.	NULL

Greenberg	NULL
,	NULL
S.	NULL
,	NULL
Chang	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Silverstein	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
3897-3902	NULL
18	NULL
.	NULL

Anegon	NULL
,	NULL
L.	NULL
,	NULL
Cuturi	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Trinchieri	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Perussia	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

167	NULL
,	NULL
452-472	NULL
19	NULL
.	NULL

Polat	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Laufer	NULL
,	NULL
J.	NULL
,	NULL
Fabian	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Passwell	NULL
,	NULL
J.	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
Immunology	NULL
80	NULL
,	NULL
287-292	NULL
20	NULL
.	NULL

Egan	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nature	NULL
365	NULL
,	NULL
781-783	NULL
21	NULL
.	NULL

Macdonald	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Crews	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Wu	NULL
,	NULL
L.	NULL
,	NULL
Driller	NULL
,	NULL
J.	NULL
,	NULL
Clark	NULL
,	NULL
R.	NULL
,	NULL
Erikson	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
McCormick	NULL
,	NULL
F.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
6615-6620	NULL
22	NULL
.	NULL

Marshall	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

4	NULL
,	NULL
82-89	NULL
23	NULL
.	NULL

Blenis	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
5889-5892	NULL
24	NULL
.	NULL

Gille	NULL
,	NULL
H.	NULL
,	NULL
Sharrocks	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
Shaw	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
858	NULL
,	NULL
414-417	NULL
25	NULL
.	NULL

Hill	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
and	NULL
Treisman	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
199-211	NULL
26	NULL
.	NULL

Durden	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Kim	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Calore	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Liu	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

154	NULL
,	NULL
4039-4047	NULL
27	NULL
.	NULL

Hirasawa	NULL
,	NULL
N.	NULL
,	NULL
Santini	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Beaven	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

154	NULL
,	NULL
5391-5402	NULL
28	NULL
.	NULL

Izquierdo	NULL
,	NULL
M.	NULL
,	NULL
Leevers	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Marshall	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
1199-1208	NULL
29	NULL
.	NULL

Casillas	NULL
,	NULL
A.	NULL
,	NULL
Hanekom	NULL
,	NULL
C.	NULL
,	NULL
Williams	NULL
,	NULL
K.	NULL
,	NULL
Katz	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Nel	NULL
,	NULL
A.	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
19088-19094	NULL
30	NULL
.	NULL

Trotta	NULL
,	NULL
R.	NULL
,	NULL
Kanakaraj	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Perussia	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184	NULL
,	NULL
1027-1035	NULL
0	NULL
w	NULL
m	NULL
1	NULL
m	NULL
pugs	NULL
to	NULL
ho	NULL
ia	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

FcR-dependent	NULL
MAPK	NULL
Activation	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
Milella	NULL
,	NULL
M.	NULL
,	NULL
Gismondi	NULL
,	NULL
A.	NULL
,	NULL
Roncaioli	NULL
,	NULL
P.	NULL
,	NULL
Bisogno	NULL
,	NULL
L.	NULL
,	NULL
Palmieri	NULL
,	NULL
G.	NULL
,	NULL
Frati	NULL
,	NULL
L.	NULL
,	NULL
Cifone	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
and	NULL
Santoni	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
8148-3154	NULL
Karimi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Lennartz	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
Inflammation	NULL
22	NULL
,	NULL
67-82	NULL
Galandrini	NULL
,	NULL
R.	NULL
,	NULL
Palmieri	NULL
,	NULL
G.	NULL
,	NULL
Piccoli	NULL
,	NULL
M.	NULL
,	NULL
Frati	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Santoni	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
,	NULL
179-186	NULL
Haskill	NULL
,	NULL
S.	NULL
,	NULL
Johnson	NULL
,	NULL
C.	NULL
,	NULL
Eierman	NULL
,	NULL
D.	NULL
,	NULL
Becker	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Warren	NULL
,	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
1690-1694	NULL
Cogawell	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Godlevski	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Wisely	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Clay	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Leesnitzer	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Ways	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Gray	NULL
,	NULL
J.	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
712-723	NULL
Hiscott	NULL
,	NULL
J.	NULL
,	NULL
Marois	NULL
,	NULL
J.	NULL
,	NULL
Garoufalis	NULL
,	NULL
J.	NULL
,	NULL
D'Addario	NULL
,	NULL
M.	NULL
,	NULL
Roulston	NULL
,	NULL
A.	NULL
,	NULL
Kwan	NULL
,	NULL
L.	NULL
,	NULL
Pepin	NULL
,	NULL
N.	NULL
,	NULL
Lacoste	NULL
,	NULL
J.	NULL
,	NULL
Nguyen	NULL
,	NULL
H.	NULL
,	NULL
Bensi	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Fenton	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
6281-6240	NULL
Khosravi-far	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Channing	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cancer	NULL
Metast	NULL
.	NULL

Rev	NULL
.	NULL

18	NULL
,	NULL
67-89	NULL
Chen	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
Huff	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
Lai	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Der	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Powers	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
2691-2698	NULL
Brtva	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
Drugan	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Terrell	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Campbell-Burk	NULL
,	NULL
S.	NULL
,	NULL
Bell	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Der	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
9809-9812	NULL
Hauser	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Westwick	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
and	NULL
Quilliam	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

255	NULL
,	NULL
412-426	NULL
Rosales	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Juliano	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

56	NULL
,	NULL
2302-2305	NULL
Schook	NULL
,	NULL
L.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Monoclonal	NULL
Antibody	NULL
Production	NULL
:	NULL
Techniques	NULL
and	NULL
Appli-cations	NULL
,	NULL
Marcel	NULL
Dekker	NULL
,	NULL
New	NULL
York	NULL
Zola	NULL
,	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Monoclonal	NULL
Antibodies	NULL
:	NULL
A	NULL
Manual	NULL
of	NULL
Techniques	NULL
,	NULL
CRC	NULL
Press	NULL
,	NULL
Boca	NULL
Raton	NULL
,	NULL
FL	NULL
.	NULL

Uehara	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Fukazawa	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

201	NULL
,	NULL
370-879	NULL
45	NULL
.	NULL

Sporn	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Eierman	NULL
,	NULL
D.	NULL
F.	NULL
,	NULL
Johnson	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Morris	NULL
,	NULL
J.	NULL
,	NULL
Martin	NULL
,	NULL
G.	NULL
,	NULL
Ladner	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Haskill	NULL
,	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
4484-4441	NULL
Vojtek	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
Hollenberg	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Cooper	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
74	NULL
,	NULL
205-214	NULL
Payne	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Roissamando	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Martino	NULL
,	NULL
P.	NULL
,	NULL
Erickson	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
Her	NULL
,	NULL
J.-H.	NULL
,	NULL
Shabanowitz	NULL
,	NULL
J.	NULL
,	NULL
Hunt	NULL
,	NULL
D.	NULL
F.	NULL
,	NULL
Weber	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Sturgill	NULL
,	NULL
T.	NULL
W.	NULL
(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
885-892	NULL
Salcedo	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
Kurosaki	NULL
,	NULL
T.	NULL
,	NULL
Kanakaraj	NULL
,	NULL
P.	NULL
,	NULL
Ravetch	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
and	NULL
Perussia	NULL
,	NULL
B	NULL
.	NULL

(	NULL
19938	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177	NULL
,	NULL
1475-1480	NULL
49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

27619	NULL
Wang	NULL
,	NULL
A.	NULL
V.	NULL
T.	NULL
,	NULL
Scholl	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
and	NULL
Gebha	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
1165-1170	NULL
Viver	NULL
,	NULL
E.	NULL
,	NULL
da	NULL
Silva	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Ackerly	NULL
,	NULL
M.	NULL
,	NULL
Levine	NULL
,	NULL
H.	NULL
,	NULL
Rudd	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
and	NULL
Anderson	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
1872-1876	NULL
Kiener	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Rankin	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Burkhardt	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Schieven	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Gilliland	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Rowley	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
19938	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
24442-24448	NULL
Darby	NULL
,	NULL
C.	NULL
,	NULL
Geahlen	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
Schreiber	NULL
,	NULL
A.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

152	NULL
,	NULL
5429-5437	NULL
Gray	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Chandra	NULL
,	NULL
G.	NULL
,	NULL
Clay	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Stinnett	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Haneline	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Lorenz	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Patel	NULL
,	NULL
I.	NULL
R.	NULL
,	NULL
Wisely	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Furdon	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Taylor	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Kost	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
6678-6689	NULL
Shirakawa	NULL
,	NULL
F.	NULL
,	NULL
Saito	NULL
,	NULL
K.	NULL
,	NULL
Bonagura	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Galson	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Fenton	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Webb	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
and	NULL
Auron	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
1832-1344	NULL
Erbe	NULL
,	NULL
D.	NULL
V.	NULL
,	NULL
Pfefferkorn	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
and	NULL
Fanger	NULL
,	NULL
M.	NULL
W.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

146	NULL
,	NULL
3145-3151	NULL
Lange-Carter	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Pleiman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Gardner	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Blumer	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
19983	NULL
)	NULL
Science	NULL
260	NULL
,	NULL
815-319	NULL
Kyriakis	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
App	NULL
,	NULL
H.	NULL
,	NULL
Zhang	NULL
,	NULL
X.-F.	NULL
,	NULL
Banerjee	NULL
,	NULL
P.	NULL
,	NULL
Brautigan	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Rapp	NULL
,	NULL
U.	NULL
R.	NULL
,	NULL
and	NULL
Avruch	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
858	NULL
,	NULL
417-421	NULL
Howe	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Leevers	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
G-mez	NULL
,	NULL
N.	NULL
,	NULL
Nakielny	NULL
,	NULL
S.	NULL
,	NULL
Cohen	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Marshall	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
335-342	NULL
Johnson	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Gardner	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Lange-Carter	NULL
,	NULL
C.	NULL
,	NULL
Qian	NULL
,	NULL
N.	NULL
X.	NULL
,	NULL
Russell	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Winitz	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

54	NULL
,	NULL
415-422	NULL
Gardner	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Vaillancourt	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
17896-17901	NULL
Crews	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
and	NULL
Erikson	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
74	NULL
,	NULL
215-217	NULL
Agarwal	NULL
,	NULL
A.	NULL
,	NULL
Salem	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Robbins	NULL
,	NULL
K.	NULL
C.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
15900-15905	NULL
Hirasawa	NULL
,	NULL
N.	NULL
,	NULL
Scharenberg	NULL
,	NULL
A.	NULL
,	NULL
Yamamura	NULL
,	NULL
H.	NULL
,	NULL
Beaven	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Kinet	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
10960-10967	NULL
Jabril-Cuenod	NULL
,	NULL
B.	NULL
,	NULL
Zhang	NULL
,	NULL
C.	NULL
,	NULL
Scharenberg	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Paolini	NULL
,	NULL
R.	NULL
,	NULL
Numerof	NULL
,	NULL
R.	NULL
,	NULL
Beaven	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Kinet	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
16268-16272	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Fcy	NULL
Receptor-mediated	NULL
Mitogen-activated	NULL
Protein	NULL
Kinase	NULL
Activation	NULL
in	NULL
Monocytes	NULL
Is	NULL
Independent	NULL
of	NULL
Ras	NULL
Gabriela	NULL
Sanchez-Mejorada	NULL
and	NULL
Carlos	NULL
Rosales	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1998	NULL
,	NULL
273:27610-27619.	NULL
doi	NULL
:	NULL
10.1074/jb0.273.42.27610	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/273/42/27610	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
61	NULL
references	NULL
,	NULL
35	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

